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CHAPTER 1 
GENERAL INTRODUCTION 
Chapter J 
Since blood transfusion became a therapeutical option in patient care, the surgical 
possibilities have increased tremendously. Since the problems of anticoagulation and blood 
group typing were largely resolved, blood transfusions were in only a minority of cases 
directly lethal. However, it was estimated that still up to 20% of the blood transfusions 
induces a sort of adverse side-effect. 1 Because the most important side-effects are a result 
of the transmission of infections and the induction of immunological reactions, these are 
further discussed. 
Blood transfusion-induced infection 
Numerous infections can be transmitted by blood transfusions. In developing countries 
bacterial and parasitic infections, such as Plasmodium (malaria), Trypanosoma cruzl 
(Chagas' disease), and Treponema Pallidum (syphilis) may occur. In the Western World 
the most important infections that may be transmitted by blood transfusions are viral 
infections. Examples of these are the hepatitis Band C virus, I human immunodeficiency 
virus (type I and type 2),' cytomegalovirus,' Epstein·Barr virus, and human T cell 
leukemia virus.4 Some of these infectious agents have great clinical impact and therefore 
blood donors should be routinely screened for them.' Since in The Netherlands all donor 
blood is tested for human immunodeficiency virus (HIV) and hepatitis Band C virus, the 
risk of hepatitis and AIDS (acquired immune deficiency syndrome) is reduced 
remarkably,6 but the transmission of these vimses by blood transfusions is still not zero. 
The chance on transmission of HIV in The Netherlands is estimated to be I in 600,000 
transfusions. 
Blood transfusion-induced immunosuppression 
A blood transfusion is a transplantation of allogeneic tissue in liquid form. Looking to 
blood transfusions in this way makes it easier to understand why blood transfusions may 
evoke immunologic reactions. If the recipient's immune system responds to the antigens 
present on transfused erythrocytes, these red cells will be hemolysed. This hemolytic 
transfusion reaction occurs mainly as a result of blood group incompatibility, and can be 
reduced to a minimum by crossmatching. Whenever an allogeneic reaction occurs due to 
sensitization against other components in the blood (leukocytes, platelets, plasma proteins), 
a non~hemolytic transfusion reaction occurs. The initial clinical manifestation of this 
reaction is fever and is usually mild. 
Patients who are on the waiting list for a kidney transplantation often need multiple blood 
transfusions due to renal failure. While investigating whether the induction of antibodies 
against HLA-antigens by allogeneic blood transfusions would cause an impaired kidney-
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graft survival. Opelz et al,' found that besides this alloimmunization also 
immunosuppression occurred. It was found that kidney-graft survival in patients receiving 
transfusions prior to surgery was as much as 20% better as compared to those patients 
who did not receive transfusions. Although its exact mechanism is still unclear, the 
immunosuppressive effect of blood transfusions has for many years been well established 
in renal transplantation.s However, after cyclosporine A was introduced as a very potent 
immunosuppressive drug the graft survival of patients who did not receive transfusions 
was improved considerably, and therefore transfusion-induced immunosuppression became 
less demonstrable. 
During the last decades many immunological changes have been held responsible for the 
immunosuppressive effect of blood transfusions. It has been found that after blood 
transfusions lymphocyte responsiveness was reduced,9 T -suppressor lymphocytes were 
increased,lo cutaneous delayed hypersensitivity was reduced,·1,12 macrophage activity 
was impaired," natural killer cell activity was depressed." etc. It also has been found 
that non-cellular mechanisms might be responsible for transfusion-induced 
immunosuppression. Prostaglandin ~ release may be increased after transfusions. 15 An 
increased level of prostaglandin Ii, is immunosuppressive due to inhibition of interleukin 
2. which decreases the function of T cells.!6.17 This influence can be mediated directly 
by interleukin 2 or indirectly via interferon-y.!' 
Although all the aforementioned mechanisms may have a role in the immunomodulatory 
effects of blood transfusions,19,20 it is important to realize that these findings cannot be 
automatically extrapolated to tumor biology.>! For example. HLA-antigens are of great 
importance in the allograft reaction, and there are indications that the transfusion effect in 
renal transplantation is dependent on a certain degree of HLA matching and mismatching 
between blood donor and recipient." However. HLA-antigens are not likely to be 
involved in the syngeneic relationship between tumor and host. 
Blood transfusions and cancer prognosis 
Gantt" speculated on a possible similarity between tumor and transplantation antigens 
and suggested in 1981. that blood transfusion-induced immunosuppression might have a 
detrimental effect on the prognosis of patients operated for solid malignancies. 
Transfusion-induced immunosuppression can alter tumor growth only if there exists a 
relationship between tumor growth and the immune system. Although most human tumors 
lack immunogenicity, it is kwown that non-specific immune responses may have antitumor 
effects. Cytokines, such as tumor necrosis factor alfa, interleukin-2 and interferon-y have 
antitumor effects. Therefore. the activated T cells and macrophages may playa role in the 
immune response against cancer cells. Rosenberg et a1.24 showed that interleukin-2 
therapy had an effect on tumor growth of melanoma and renal cell cancer. Also natural 
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killer cells have shown to have antitumor effect in vitro. It is conceivable, that blood 
transfusions mediate tumor growth by altering the nOllwspecific immune response. 
Additionally, it is found that in colorectal cancer patinets immunotherapy may be a 
clinical possibility for treatment. The study by Moertel et al." and the study by Laurie et 
al." demonstrated that there is some therapeutical effect of the immunomodulator 
Levamisole in combination with Fluorouracil in patients operated for colorectal cancer. 
Immunotherapy using lymphokine activated killer cells is believed to be effective in 
patients with advanced colorectal cancer." It is also found that adjuvant therapy with 
monoclonal antibodies extends life and prolongs remission in patients with colorectal 
cancer of Dukes' C stage.28 The increased survival after these treatments suggests a 
relationship between colorectal cancer prognosis and immune functions. Therefore, the 
statement that blood transfusions modulate tumor growth has stimulated many 
investigators to unravel this postulation in either experimental or clinical studies. 
Experimental studies 
Because of their ability to control for factors such as tumor load, transfusion policy. and 
surgical extent, experimental studies are the best way to explore a direct effect of blood 
transfusions on tumor growth. However, the animal studies on tumor growth and blood 
transfusions showed a great variety in results. Francis et al.29 found that tumor growth 
was potentiated by allogeneic blood transfusions in a rat model. However, in another rat 
model an inhibitory effect of allogeneic transfusions on pulmonary metastases was 
demonstrated by Jeekel et a1.3O, whereas there was no effect on subcutaneously implanted 
tumors in the same rat strain. Oikawa et al.31 also did not find an effect on 
subcutaneously implanted tumors. In these models blood transfusions were given before 
tumor inoculation. It was also found in rat studies that allogeneic blood transfusions 
increased tumor growth only when the transfusion was given after tumor 
inoculation?2,33 In a mouse tumor model it was found that blood transfusions had a 
tumor promoting effect when given prior to tumor inoculation.H However, Zeller et al.3S 
found contradictory results in several other mouse models. Blood transfusions given after 
tumor inoculation in mice has also demonstrated to have stimulatory effects on tumor 
growth." All these different animal studies using different models thus have shown an 
inhibitory, a tumor promoting, or no effect of blood transfusions. Therefore, the presence 
of a blood transfusion effect on tumor growth seems to be dependent on the kind of 
tumor, the route of tumor inoculation, and the animal species used.31 To investigate 
which blood component could be responsible for a tumor promoting effect animal studies 
were performed in our laboratory. It was shown that a tumor promoting effect of 
allogeneic blood transfusions was evoked by the transfusion of erythrocytes, leukocytes 
and of whole blood whereas transfusion of plasma had no effect on tumor growth." 
The finding that some animal models showed a tumor promoting effect of blood 
transfusions suggests that there indeed might be a clinical situation in which there is an 
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effect of blood transfusions on tumor recurrence. However, it should be realized that blood 
transfusions are always given for a particular reason. One of the most common reasons for 
transfusion is a certain amount of blood loss. It is found that blood loss itself may have 
inununosuppressive effects. It is also shown by experiments from our own laboratory that 
blood loss affected tumor growth, irrespective whether transfusions were given or 
not,,,·40 The amount of blood loss during surgery could be related to the extend of the 
surgical trauma. Also the extend of the surgical trauma itself can have inununomodulatory 
effects, showing that the complexity of the inununological changes after an operation 
includes the effects of blood transfusions, blood loss and surgery. If blood loss during 
surgery is comparable to the donation of blood this might have clinical consequences 
when predeposit autologous blood donation is use to reduce the exposure to allogeneic 
transfusions (see further in this chapter). 
Clinical studies 
The first retrospective study on the effect of blood transfusions and colorectal cancer 
prognosis was reported by Burrows and Tartter.41 The diseaseMfree survival rate in 
transfused patients was significantly worse than in patients who did not receive 
transfusions; diseaseMfree survival at 5 years was 51% and 84%, respectively. After this 
initial report many clinical studies were performed in a variety of tumors. Most of these 
studies had a retrospective design and dealt with colorectal cancer. Several reports 
reviewed over 30 of these studies.42,43,44,45,46.47 A significant adverse effect of blood 
transfusions was found in a little more than 50% of the studies whereas the other studies 
showed no significant effect and even in one study blood transfusions even had a 
beneficial effect on prognosis." In most of these papers multivariate analysis was used to 
control for various prognostic factors. In some studies, the significant difference observed 
in univariate analysis, disappeared when multivariate analysis allowing for various factors 
was performed.49,50 
Clinical studies reporting a transfusion effect on prognosis cannot differentiate between a 
causal or an indirect relationship. The latter means that the outcomes were biased by the 
selection of patients, since patients were transfused either by nature of their disease or by 
the kind of operation performed. Clearly, multivariate analysis cannot control for factors 
which are either unknown or difficult to quantify. Factors such as the preoperative 
condition and the host defence of a patient can only partly be represented by determinants 
such as age, hemoglobin level, tumor stage, and inununologic parameters. Nevertheless, 
such factors might influence the recovery and the prognosis of cancer patients as well. 
Therefore the effect of blood tmnsfusions might be an epiphenomenon, meaning that it is 
only an indicator of prognostic factors, which could not be adjusted for. Therefore, 
performing multivariate analysis in the present circumstances cannot reveal whether blood 
transfusions are causative of a worse prognosis. It can only demonstrate whether they are 
of additional prognostic value when other known prognostic factors are taken into account. 
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Obviously, the need for transfusions is related to perioperative blood loss and, therefore, 
with difficulties during operation, which might be related to the tumor or the surgeon,51 
The extent of a resection and thereby the surgical trauma, reflected by an increased need 
for transfusions, could be of importance for the patients recovery and also for the induced 
immunosuppression, which might affect the prognosis. Only a few studies included the 
extent of operation by allowing for duration of surgery. Parrott et al." found that 
duration of surgery was significantly related to blood transfusions. However, there was no 
relationship demonstrated between duration of surgery and prognosis, whereas blood 
transfusion was a strong predictor of recurrence. Another surrogate marker of surgical 
extent is blood loss. Tilis factor, however, is strongly correlated with blood transfusions. 
Therefore blood transfusions and blood loss are difficult to evaluate separately in clinical 
studies, but as was shown in animal experiments the factor blood loss might be relevant 
for peri operative immunosuppression. 
In some studies, including the one from our hospital,S3 it was suggested that the 
transfusion effect might be due to an increased amount of patients with rectal tumors in 
the transfused group, who apparently have a worse prognosis. Controlling for tumor 
location in multivariate analysis, however, it was found that blood transfusion was an 
independent factor. In addition, there are several reports which dealt only with colonic 
cancer which also found a detrimental effect of blood transfusions.54.55 
Voogt et a1.56 found that overall survival was affected by transfusions whereas cancer 
related death was not. This finding, which is confirmed by others," suggests that there 
are other factors related to transfusions which are unfavorable for prognosis regarding 
other causes of death. 
n had been suggested that the studies which did not find a significant effect of 
transfusions were too small in number of patients to show an effect, due to a too large 
probability of a type II error. Indeed, several of these studies were rather small but there 
were also studies including over 500 patients in which no effect of blood transfusions was 
found.58.59 
Recently two meta-analyses on these clinical studies were published. The great advantage 
of a meta-analysis is that the sample size is increased considerably. In a meta-analysis 
which investigates the effect of blood transfusions on colorectal cancer, however, all the 
disadvantages related to observational studies still persist. Furthermore, only a few of the 
studies were prospective in design.60·61 Therefore, a meta-analysis of all these studies 
cannot establish whether a negative association between blood transfusions and cancer 
prognosis is causal or not. Also, the phenomenon of publication bias (publication of 
positive outcomes might be more likely, leading to an underrepresentation of negative 
studies) is a potential problem in any meta-analysis. 
In the study by Chung et al." a total of 20 papers were reviewed, including over 5000 
patients. The authors found that the cumulative odds-ratio of negative outcomes after 
perioperative blood transfusions was 1.80 for recurrence and 1.76 for death from cancer 
14 
General introduction 
(both p<O.OOI). The authors recognized that their results did not resolve the question of 
causality, but their analysis well defined the magnitude of the transfusion effect. 
In the meta-analysis by Vamvakas and Moore63 the data of II clinical studies were 
pooled and the studies in which possible confounders were not specified were left out 
from their analysis. Although the studies used in this analysis were the ones with good 
controlling for confounders, the study still showed a significant increase in the combined 
risk of cancer recurrence or cancer related death in the transfused patients of 37%. Yet the 
authors concluded that, considering the extent of residual confounding present in the 
pooled results, this entire average transfusion effect could be ascribed to the effect of 
uncontrolled confounding. Although these meta-analyses showed a significant negative 
relationship between blood transfusions and colorectal cancer prognosis, both studies are 
inconclusive with regard to the causality of this relationship. 
Recently Houbiers et aI.'" presented a meta-analysis in which possible confounders are 
identified by analysing differences between subgroups of patients. It was suggested that 
more left sided tumors, more Dukes' C tumors, and older patients were present in the 
transfused group. These imbalances could explain the worse prognosis of transfused 
patients as compared with patients who did not receive transfusions. 
After so many cHnical reports investigating the association between blood transfusions and 
prognosis in colorectal cancer patients the exact solution for this clinical important 
problem is still not given. 
Blood transfusions and postoperative infectious complications 
Transfusion-induced immunosuppression might increase the susceptibility to bacterial 
infectious complications after surgical procedures. Tartter65 was the first to demonstrate 
that in colorectal cancer patients who were transfused the rate of postoperative infectious 
complications was increased as compared with those patients who did not receive 
transfusions; infectious complications occurred in 25% and 4%, respectively. Multivariate 
analysis identified blood transfusion and hematocrit as significant independent risk factors 
for infections. Surprisingly, the patients with normal hematocrits who received transfusion 
had the highest rate of infections (33%). Wobbes et al." found that the patients with 
multiple transfusions (over 4 units) had the highest rate of infections, and stated that the 
amount of transfusions was important for the increased susceptibility to infections. 
Transfusions also were a significant predictor of postoperative infections in patients with 
abdominal trauma or burn wounds67,6S and transfusion even was a predictor of infections 
in patients transfused for gastrointestinal hemorrhage without surgery." That the 
increased susceptibility to infections may be a result of transfusion-induced 
immunosupression has been supported by several animal studies. Waymack et a1.70.71 
found that the function of macrophages was impaired by blood transfusion and that the 
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resistance to bacterial peritonitis was decreased after allogeneic blood transfusions. 
However, as for cancer recurrence the same limitations of these studies applied for 
infectious complications in relation to blood transfusions. Statistical analysis can evaluate 
different risk factors simultaneously and predict whether these factors have an independent 
effect. It is, however, impossible to exclude interactions between different variables. For 
example, the risk of infections is related to the extent of the operation, the amount of 
blood loss, and whether transfusion are given or not. These factors are that strong related 
to each other that it is difficult to point out which one is responsible for increased 
susceptibility to infections. 
Alternatives for allogeneic blood transfusion 
Being aware of the risks of allogeneic blood transfusions made clinicians try to reduce the 
exposure to allogeneic blood to a minimum. Naturally, blood transfusions should only be 
given when it is absolutely necessary. Tartter et a1.12 determined that 25% of the blood 
transfusions in colorectal cancer surgery were unnecessary and could be prevented by 
simply checking the hematocrit before transfusion. The most logical but not always 
possible solution will be the reduction of blood loss. Besides meticulous surgery and 
hemostatis serveral anesthesiologic techniques has been performed to reduce blood loss. 
For example, controlled hypotension, positioning methods, and regional anesthesia. Also 
drugs such as aprotinin. dipyridamole. and desmopressine have shown to have some value 
in reducing pedoperative blood loss. However, for a large group of patients transfusions 
are still required and therefore it is worthwhile looking for the best alternative for 
allogeneic blood. 
Allt%golls blood tralls/IISiOIlS 
Since autologous blood transfusions are, undoubtedly, the safest blood to transfuse several 
techniques have been performed to obtain autologous blood for transfusion. 
Autologous blood transfusion can be performed in three ways: 
1. Predeposit autologous blood donation, by which blood is collected by preoperative 
phlebotomies. This procedure has great popularity because of its safety. Although some 
studies doubted whether this is suitable in colorecta! cancer patients," it showed to 
reduce the exposure to allogeneic blood remarkably.74." Predeposit autologous blood 
donation can be potentiated by the use of recombinant human erythropoietin,76.71 which 
by itself also can reduce the need for transfusions perioperatively.78.79 
2. Hemodilution, by which blood can be withdrawn immediately preoperatively or 
intraoperatively. The circulation will remain normovolemic due to infusion of colloid 
solutions. Hemodilution also can be performed hypervolemicly, by which no blood is 
withdrawn but as a result of colloid infusion the hematocrit is lowered and therefore the 
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loss of erythrocytes is reduced during surgery. This method has proven its value in 
Jehovah's Witnesses who refuse blood transfusions of any type.so 
3. Intraoperative blood salvage from the operation field by means of a cell saver. The 
latter has proven to be a very useful way in reducing exposure to allogeneic blood 
especially in vascular and orthopedic surgery.8! However, because of the fear of 
transfusing cancer cells and microorganisms into the patient's circulation the value of this 
technique in colorectal cancer surgery is questionable. 
Aims of the studies 
As discussed above the material present· in the literature about the effect of blood 
transfusion-induced immunosuppression on the prognosis of cancer patients is still 
inconclusive. Several retrospective studies indeed found that blood transfusions are related 
to a poor prognosis in colorectal cancer patients. Experimental studies showed that growth 
of certain tumors was enhanced after allogeneic blood transfusions, which suggests that the 
relationship between blood transfusions and impaired cancer survival might be causal. 
However, there are also conflicting data from both experimental and clinical studies. 
Transfusions are given either because of the disease or as a result of surgical treatment. 
Therefore it is questionable, whenever a relationship between transfusions and cancer 
prognosis would exist, whether this relationship is causal or indirect. The need for 
transfusion could be all indicator of other prognostic factors, which are unknown, and 
therefore blood transfusion is coincidentally related to prognosis. The only way to resolve 
the question of causality is to perform a randomized trial comparing transfused patients 
with patients who did receive transfusions. Unfortunately, it is disputable whether such a 
trial design is ethically justified. Although the causality of the putative relationship can not 
be resolved completely it is possible to investigate whether the effects of allogeneic blood 
transfusions can be overcome. We have chosen predeposit autologous blood transfusion as 
the alternative for allogeneic blood transfusions in colorectal cancer surgery. This choice 
was based on the experimental findings that autologous blood transfusions are 
immunological neutral. 82.83 Therefore, the use of a predeposit autologous blood 
transfusion program could be an option to overcome the putative detrimental effects of 
allogeneic blood transfusions in colorectal cancer patients. The proper way to investigate 
the value of this method is a randomized trial. 
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The aims of the studies presented in this thesis are in the first place, to investigate whether 
the reduction of the exposure to allogeneic blood transfusions by means of a predeposit 
autologous blood donation program: 
1. Can improve the survival in colorectal cancer patients (Chapter 2). 
2. Can increase the disease-free survival in colorectal cancer patients (Chapter 2). 
3. Can decrease the rate of postoperative infectious complications after colorectal 
cancer surgery (Chapter 5). 
Secondly I it is tried to elucidate the putative detrimental relationship between: 
1. Blood transfusions and colorectal cancer prognosis (Chapter 2, 3, and 4). 
2. Blood transfusions and postoperative infectious complications after colorectal 
cancer surgery (Chapter 5). 
Thirdly, to investigate whether autologous blood donation itself: 
1. Can affect the immunological status of colorectal cancer patients (Chapter 6). 
2. Can affect the prognosis and infectious complications after colorectal cancer 
surgery (Chapter 7). 
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Chapter 2 
Summary 
Blood transfusions may adversely affect the prognosis of patients treated surgically for 
cancer, although definite proof of this adverse effect has not been reported. 
We carried out a randomized trial to investigate whether the prognosis in patients with 
colorectal cancer would be improved by a program of autologous blood transfusion as 
compared with the current practice of allogeneic transfusion. Patients in the autologous 
group were required to donate two units of blood before surgery. 
A total of 475 patients were evaluated. We found no significant difference in prognosis 
between the allogeneic group (N=236) and the autologous group (N=239); colorectal 
cancer-specific survival rates at 4 years were 67% and 62%, respectively (p=O.39). Among 
the 423 patients who underwent curative surgery, 66% of those in the allogeneic group 
and 63% of those in the autologous group had no recurrence of colorectal cancer at 4 
years (p=O.93). 
We also found that the risk of recurrence was significantly increased in patients who 
received blood transfusions, either allogeneic or autologous. as compared with patients 
who did not require transfusions; the relative recurrence rates were 2.1 (p=O.OI) and 1.8 
(p=O.04), respectively; these rates did not differ significantly from each other. 
The use of autologous blood as compared with allogeneic blood for transfusion does not 
improve the prognosis in patients with colorectal cancer. Regardless of their type, 
transfusions are associated with poor prognosis, probably because of the circumstances that 
necessitate them. 
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Introduction 
Perioperative blood transfusions may have a deleterious effect on the survival of patients 
with a variety of solid tumors,1,2 possibly because of an immunosuppressive effect.3.4 
This possibility is supported by studies in animals in which tumor growth was enhanced 
after allogeneic transfusion,s,6 although conflicting results have also been reported.7,8 A 
poor prognosis after blood transfusions has been noted especially in patients with 
colorectal cancer. 
In the studies of the effect of blood transfusions in patients with cancer, the patients were 
given the transfusions either because of their disease or because transfusion was necessary 
during surgical treatment. Therefore, the question remains whether the relation between 
blood transfusion and poor prognosis is causal or coincidental.9 The need for transfusion 
could be an indicator of other prognostic factors that are either unknown or difficult to 
quantify, such as the extent of the tumor and the dissection, the skill of the surgeon, and 
the nutritional state of the patient. 
A randomized trial is the only way in which possible bias in the selection of patients can 
be avoided. Randomization between transfusion and no transfusion is impossible, however, 
because giving patients transfusions when there is no medical indication and withholding 
transfusions that are indicated are ethically unacceptable. Since autologous blood is the 
safest blood to use in transfusion, comparing the effects of allogeneic and autologous 
blood transfusions would be a logical option. 
We therefore conducted a randomized multicenter trial in patients with colorectal cancer to 
determine whether autologous blood transfusion would reduce the rate of recurrence of 
cancer and improve the survival as compared with allogeneic transfusion. We previously 
reported that a notable reduction in the number of allogeneic transfusions can be achieved 
with a program of autologous blood transfusion. 1O 
Methods 
The study was conducted in 14 hospitals in The Netherlands and I hospital in England 
and was approved by the ethics committees of all the participating hospitals. After written 
informed consent had been obtained, eligible patients were randomly assigned to either the 
allogeneic group or the autologous group, with stratification according to participating 
hospital. Patients were enrolled from August 1986 to November 1991, when the planned 
enrollment was reached. 
Eligibility of patiellts 
Patients scheduled for a potentially curative resection of cancer of the colon or rectum 
were eligible for enrollment if they fulfilled the criteria of the American Association of 
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Blood Banks for autologous blood donation in anticipation of surgery.l1 These criteria 
required the absence of severe cardiovascular or respiratory disease, no history of epilepsy 
after infancy. and a hemoglobin concentration above 11.3 gldl (7 mmol!l). In addition. 
patients had to have no evidence of metastatic disease. on the basis of chest radiography 
and ultrasonography of the liver; no other cancer except basal-cell carcinoma of the skin 
or in situ carcinoma of the cervix; no evidence of ulcerative colitis, familial polyposis, or 
a fixed rectal carcinoma requiring preoperative radiation therapy; and no history of blood 
transfusion during the three months before randomization. No adjuvant therapy was 
allowed except irradiation. If metastatic or recurrent disease developed in a patient during 
follow-up. all available therapies were allowed. 
Procedures for donation and tralls/usion 
Patients randomly assigned to the autologous group were required to donate blood twice. 
The minimal interval between the two donations was 72 hours, and the second donation 
had to occur not later than five days before surgery. At each donation. 450 ml of blood 
was obtained by standard procedures. The patients were treated with oral iron 
supplementation immediately after randomization. 
The collected blood was separated into packed red cells and fresh-frozen plasma. except at 
one hospital. where autologous blood was given in transfusion as whole blood. The packed 
red cells and whole blood were stored at 4'C. Allogeneic blood was always given in 
transfusion as packed red cells. Standard rules for transfusion were used for both groups. 
Packed red cells could be given only if the loss of blood exceeded 500 ml or if the 
hemoglobin concentration dropped below 10.5 gldl (6.5 mmolll). If this hemoglobin 
concentration was not achieved after two autologous transfusions, additional allogeneic 
transfusions were made. In both groups fresh-frozen plasma was given when indicated. 
Surgery alld Mstopath%gica/ assessment 
Standard surgical procedures were used. The operative specimens were classified 
according to Dukes' classification as modified by Turnbull." A tumor confined to the 
bowel wall was classified as Dukes' A; a tumor extending through the serosa into the 
pericolic fat as Dukes' B; the presence of regional lymph nodes containing metastases as 
Dukes' C; and the presence of distant metastases or unresectable tumor as Dukes' D. All 
patients who had residual tumor evident only on microscopical examination received 
postoperative radiotherapy. These patients and those who had en bloc resection of adjacent 
organs were not considered as having Dukes' D. but rather as having Dukes' B or C 
disease. 
Follow-up and criteria for recurrent cancer 
The patients were evaluated every three months during the first two years after surgery 
and every six months thereafter. Each evaluation consisted of a history. a physical 
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examination, and blood tests (to measure the concentrations of hemoglobin and serum 
carcino-embryonic antigen). Ultrasonography of the liver was performed every six months 
for three years and each year thereafter. Chest films and colonoscopy were done yearly. 
Characteristic abnormalities detected on physical examination or on chest radiography, 
liver ultrasonography, or abdominal computed tomography were accepted as evidence of 
metastatic or recurrent disease. If possible, the presence of metastatic or recurrent disease 
was conflfmed by histologic or cytologic examination. Increased serum concentrations of 
carcino-embryonic antigen without evidence of recurrence at suspected anatomical sites 
were not considered to indicate metastatic or recurrent disease. 
Statistical analysis 
Categorical data were compared by the chi-square test, and continuous data by the Mann-
Whitney test. The major end points were disease-free survival and colorectal cancer-
specific survival (including as events all patients who died of colorectal cancer, without 
regard to other causes of death), both as determined from the time of surgery and 
calculated according to the Kaplan-Meier method. The log-rank test was used to compare 
these end points. Multivariate analysis was performed by proportional-hazards analysis13 
to obtain a higher level of precision in the comparison of the randomized groups. Two-
sided p values of 0.05 or less were considered statistically significant. P values calculated 
with adjustment for Dukes' stage are indicated as adjusted p values in the text. 
Patients in whom a secondary primary tumor developed outside the colon were withdrawn 
from study with regard to the calculation of disease-free survival. Metachronous tumors in 
the colon, however, were defined as representing recurrent disease. Postoperative deaths, 
defined as deaths occurring within 30 days after surgery, and deaths occurring more than 
30 days after surgery due to postoperative complications were counted as deaths due to 
cancer. 
Because the analysis of overall survival and colorectal cancer-specific survival gave 
similar results, only the results of colorectal cancer-specific survival are reported. 
Except for the patients who did not have colorectal cancer at the time of surgery, all 
randomized patients were primarily evaluated according to the intention-to-treat principle. 
In addition, exploratory analyses were performed according to the number and type of 
transfusions received. 
Results 
Characteristics of the patients 
A total of 510 patients were enrolled in the study. Thirty-five patients (7%) were excluded 
because they did not have colorectal cancer at the time of surgery. The characteristics of 
the remaining 475 patients are shown in Table 2.1. 
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Table 2.1. Characteristics of the patients with colorectal cancer in the allogeneic and 
autologous groups. 
Allogeneic group Autologous group 
(N = 236) (N = 239) 
Median age (years, range) 68 (33-89) 66 (3 t-88) 
Sex 
Male t32 (56%) 141 (59%) 
Female 104 (44%) 98 (41%) 
Tumor location 
Ascending colon 24 (10%) 16 (7%) 
Flexures and transverse colon t2 (5%) t6 (7%) 
Descending colon and sigmoid 62 (26%) 65 (27%) 
Rectosigmoid and rectum t32 (56%) 135 (56%) 
Multiple primary tumors 6 (3%) 7 (3%) 
Dukes' classification . 
A 53 (23%) 55 (23%) 
B 85 (36%) 80 (34%) 
C 78 (33%) 72 (31%) 
D t8 (8%) 29 (12%) 
Histologic differentiation 
Well 35 (t5%) 33 (14%) 
Moderate 169 (72%) 172 (72%) 
Poor 29 (12%) 29 (12%) 
Unknown 3 (1%) 5 (2%) 
Adjacent organ fixation .. 15 (7%) 17 (8%) 
Adjuvant irradiation 15 (7%) 16 (8%) 
Does not include patients who did not undergo surgery (two in the allogeneic group and three in the 
autologous group), 
Does not include patients with Dukes' D stage. 
None of the characteristics differed significantly between the two groups. Twenty-six of 
the 239 patients in the autologous group (11%) did not donate blood; the majority of these 
were refused by the blood bank because they did not fulfill the criteria of the American 
Association of Blood Banks. These patients were included in all analyses according to the 
intention-to-treat principle. as were all patients with metastatic disease or unresectable 
tumors. The median follow-up period was 2.5 years (range, I to 59 months), and no 
patient was lost to follow-up. 
The perioperative hematologic values and use of transfusions are shown in Table 2.2. The 
number of patients in the autologous group who received allogeneic blood was half the 
number in the allogeneic group (28% vs. 56%, respectively; p<O.OOl). 
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Table 2,2, Hemoglobin concentrations, blood loss, and transfusions in patients with 
colorectal cancer in the allogeneic and autologous groups. 
Allogeneic group Autologous group p value 
Hemoglobin concentration (gldl) 
Base-line 14.5 (10,5-18.0) 14.4 (10.7-18.5) n.s. 
Immediately preoperative 14.1 (9.5-18.0) 12.5 (8.4-16.4) <0.001 
Discharge 12.5 (9.2-17.2) 12.2 (9.2-16.2) n.s. 
Blood loss (mf) 775 (100-11,500) 750 (100-6,500) n.s. 
Transfusions 
None 103 (44%) 61 (26%) <0.001 
Only autologous 112 (47%) 
Allogeneic 133 (56%) 66 (28%) <0.001 
Hemoglobin concentrations and blood loss values are shown as medians with ranges in parentheses, and 
transfusions are shown as numbers of patients with percentages in parentheses. 
Morbidity aud mortality 
Five eligible palients (two in Ihe allogeneic group and Ihree in the autologous group) did 
not have surgery, Four had more advauced disease than expected, and one patient died 
before surgery. Eight patients (three in the allogeneic group and five in the autologous 
group) died of postoperative complications. Postoperative infectious complications 
occurred in 26% of the patients (25% in the allogeneic group and 27% in the autologous 
group). There were no statistically significant differences between the two groups with 
respect to postoperative mortality and infectious complications. 
DiseaseJree survival 
Of the 423 patients who underwent curative surgery (216 in the allogeneic group and 207 
in the autologous group), 105 (54 in the allogeneic group and 51 in the autologous group) 
had recurrent disease (including three metachronous tumors). The disease-free survival of 
these 423 patients is shown in Figure 2,1. The plots for the two groups were almost 
identical (p=0.93). Also, there were no differences with regard to disease-free survival in 
each of the Dukes' stages. After adjusting for various factors, the multivariate analysis 
also revealed no difference between the groups in disease-free survival (Table 2.3). Six 
patients (two in the allogeneic group and four in the autologous group) had second 
primary tumors outside the colon during follow-up. 
To explore the relation between blood transfusions and disease-free survival, we grouped 
the patients who underwent curative surgery according to the number and type of 
transfusions they received. The disease-free survival in the 143 patients who received no 
transfusions was significantly better (adjusted p=O.OOI) than that in the 280 who did 
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receive transfusions; at 4 years, it was 73% and 59%, respectively. Among the 280 
patients who had transfusions, 136 received only allogeneic transfusions, 102 only 
autologous transfusions, and 42 transfusions of both types. The disease-free survival at 4 
years in these three groups was 56%, 62%, and 66%, respectively (adjusted p=0.50). No 
significant difference was found between the 49 patients who received no ttansfusions in 
the autologous group and the 94 such patients in the allogeneic group; the disease-free 
survival in these patients at 4 years was 69% and 75%, respectively. 
Figure 2.1. Disease-free survival of all 423 colorectal cancer patients who underwent 
curative surgery comparing randomization. 
The disease-free survival at 4 years is 66% in the allogeneic group and 63% in the 
autologous group (p=0.93). The 95% confidence interval for the difference (autologous 
minus allogeneic) between these percentages ranged from -16% to +10%. 
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Prognosis 
Because the number of autologous transfusions was limited to two, further comparisons 
were made between the 75 patients in the allogeneic group who received one or two 
allogeneic transfusions and the 102 patients in the autologous group who received one or 
two autologous transfusions but no allogeneic transfusions. The disease-free survival was 
significantly worse in the patients in both groups who received transfusions than in the 
143 patients who did not, whereas the disease-free survival of the patients who received 
transfusions in both groups did not differ significantly from each other (Table 2.4). 
Analysis of the results with respect to the use of fresh-frozen plasma revealed no relation 
between its use and disease-free survival. This was true whether the patients received 
blood transfusions Of not. 
Table 2.3. Multivariate analysis of factors with respect to disease-free survival in 423 
patients with colorectal cancer who underwent curative surgery.* 
Factor Relative 
recurrence 
rate 
Randomization 
Allogeneic group 1 
Autologous group 1.1 
Dukes' classification 
A 1 
B 4.0 
C 10.8 
95% 
confidence 
interval 
0.7 - 1.6 
1.7 - 9.5 
4.7 - 25.1 
p value 
0.74 
0.002 
<0.001 
Other factors investigated (age and sex of patients, tumor location, adjacent organ fixation, 
degree of differentiation and size of the tumor) were of no significant additional predictive 
value with respect to disease-free survival, and the effect of randomization was not 
significantly influenced by any of these factors. 
Colorectal cancer-specific survival 
During the study, 114 patients died of colorectal cancer (53 in the allogeneic group and 61 
in the autologous group). The survival of all 475 eligible patients in the two groups was 
similar (p=0.39) (Figure 2.2). 
In addition to the Dukes' stage, the patient's age was also significantly related to 
colorectal cancer-specific survival (i.e., older patients generally did worse than younger 
ones). The ratio of the death rate in the autologous group to the death rate in the 
allogeneic group, after adjustment for Dukes' stage and age, was 1.1 (95% confidence 
interval, 0.8 to 1.7; p=0.66). 
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Figure 2.2. Colorectal cancer-specific survival of all 475 colorectal cancer patients 
comparing randomization. 
The survival at 4 years is 67% in the allogeneic group and 62% in the autologous group 
(p=O.39). The 95% confidence interval for the difference (autologous minus allogeneic) 
between these percentages ranged from -18% to +7%. 
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As was the case for disease-free survival, the colorectal cancer-specific survival in the 423 
patients who underwent curative surgery was significantly better (adjusted p<O.OOI) in the 
patients who did not receive transfusion than in those who did; the survival at 4 years was 
88% and 65%. respectively. When the patients who received transfusions were subdivided 
according to the type of transfusions they received (allogeneic. autologous. or both), there 
were no significant differences (adjusted p=O.60) between the three subgroups; the survival 
at 4 years was 64%, 68%, and 63%, respectively. The survival of patients who did not 
receive transfusions did not differ significantly (adjusted p=O.86) between the two 
randomized groups; the survival of these patients at 4 years was 87% in the allogeneic 
group and 88% in the autologous group. 
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When the analysis was restricted to patients who had one or two transfusions of the same 
type, the patients receiving autologous transfusions and those receiving allogeneic 
transfusions both had worse survival rates than the patients without transfusions (Table 
2.4). 
No relation was found between survival and the transfusion of fresh-frozen plasma. 
Table 2.4. Disease-free survival and colorectal cancer-specific survival according to 
transfusion status and Dukes' classification, in patients with colorectal 
cancer who underwent curative surgery. 
Factor Number Disease-free Relative Survival Relative 
of survival. recurrence at 4 death 
patients at 4 rate' years rate' 
years 
Transfusions 
None 143 73% 88% 
1 or 2 allogeneic 75 59% 2,1+ 67% 3,6+ 
1 or 2 autologous 102 62% 1.8f~ 68% 2.8*~ 
Dukes' classification 
A 78 93% 94% I 
B 130 73% 4.3+ 85% 1.2 
C 112 39% 15,5+ 50% to.8f 
Relative rates of recurrence and death obtained by multivariate analysis. 
Significantly (p<O.05) different from no transfusions, 
Not significantly different (p>O.60) from the group receiving 1 or 2 allogeneic transfusions. 
DiscussIon 
The results of Ihe retrospective studies of Ihe influence of blood transfusions on the 
survival and the recurrence rate in patients with colorectal cancer are conflicting. The 
studies in which the prognosis in patients receiving transfusions was poorer may have 
been biased by the selection of patienls.I'.Il One way to avoid such confounding by 
indication l6 is to conduct a randomized trial comparing the effects of autologous and 
allogeneic blood transfusions. 17•I' The results of this study indicate that as compared 
with the use of allogeneic blood, the use of autologous blood either to avoid or 10 reduce 
exposure to allogeneic blood neither lowered the recurrence rate nor improved survival in 
patients who had undergone surgery for colorectal cancer. In accordance with some 
retrospective studies, the recurrence rate was higher in patients who had received 
transfusions than in those who had not. For patients given transfusions with allogeneic 
blood, the increase in the recurrence rate was similar to that in the patients who received 
only autologous blood. The same applied to Ihe survival of the patients. 
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Recently, Ness et al. 19 reported no difference in survival in a nonrandomized study in 
which the effects of allogeneic and autologous blood were compared in patients 
undergoing radical surgery for prostate cancer. The results of a randomized study 
comparing both types of transfusion in patients with colorectal cancer was also presented 
recently.20 In that study. which included only 120 patients, there were fewer recurrences 
in the autologous group, but on the basis of life-table analysis there were no statistically 
significant differences between the randomized groups. 
An explanation for our findings could be that autologous blood induces the same adverse 
reactions as allogeneic blood. In animals in which allogeneic transfusions had an adverse 
effect, no such effect was described for syngeneic blood transfusions.2Ion Since 
autologous blood transfusions in humans are comparable to syngeneic transfusions in 
animals, there is no experimental support for an effect of autologous transfusions on tumor 
growth. On the other hand, autologous transfusion requires the donation of blood. We have 
found in rats that the donation of blood can decrease natural killer cell activity and 
stimulate tumor growth?3,24,25 Therefore, the patients in the autologous group could 
have had a lower natural killer cell activity than the patients in the allogeneic group at the 
time of surgery. However, among the patients who did not receive transfusions, there was 
no difference in survival between the patients in the autologous group, who donated blood, 
and those in the allogeneic group. 
The most likely explanation for our findings is that there is no causal relation between 
blood transfusions and prognosis in patients with colorectal cancer. Thus, the findings in 
the retrospective studies in which blood transfusion was a determinant of prognosis were 
probably due to patient selection. We think it is not the blood transfusions themselves, but 
rather the circumstances necessitating the transfusions, that are the real determinant of 
prognosis. The need, to give patients transfusions during the perioperative period is 
obviously determined by a number of factors, such as blood loss, the extent of the tumor 
and the dissection, and the skill of the surgeon, although we found tumor size not to be a 
determinant of prognosis in multivariate analysis. In some retrospective studies the groups 
receiving transfusions contained more patients with rectal tumors, who have a poorer 
prognosis than patients with colon cancer, than did the groups not recelvmg 
transfusions.26,21 We found that the higher recurrence rates in both groups receiving 
transfusions, as compared with the rate in the group receiving no transfusions, were not 
affected by the location of the tumor. Because of our rules regarding transfusion, there 
was such a strong relation between blood loss and transfusion that it was impossible to 
separate these two factors. Other possible reasons for transfusion, such as the extent of the 
dissection and the skill of the surgeon are difficult to assess. Although it seems beneficial 
to operate on- patients with colorectal cancer in such a way that blood transfusions are 
either avoided or minimized, there is no reason, with respect to either cancer recurrence or 
survival, to use a program of transfusion with autologous blood in patients undergoing 
surgery for colorectal cancer. 
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Prognosis 
W.B. Ross, Ch.M. 
St. George Hospital, Kogarah, Sydney 2217, Australia 
To the Editor: 
Busch et al. (May 13 issue)' fail to consider the possibility that both autologous and 
allogeneic blood may contain an immunosuppressive factor that could influence the rate of 
recurrence of colorectal cancer. Until recently, it was generally thought that the cellular 
components of transfused blood were responsible for the immunomodulatory effects of 
transfusion, particularly in renal transplantation. Evidence is accumulating, however, to 
implicate other components. In colorectal cancer, transfusions of plasma protein fractions 
and fresh-frozen plasma have been associated with increased tumor recurrence.2.3 
Experimental work suggests that humoral rather than cellular components may be more 
important in transfusion-associated immunosuppression, although this has not yet been 
shown in tumors in animals. In rats that undergo transfusion, the effects of pretransfusion 
storage of blood on the synthesis of prostaglandin E, by macrophages were greater than 
the effects due to genetic differences between blood donor and recipient.' Serum had the 
most potent effect, indicating that a major factor activating prostaglandin E,-mediated 
immunosuppression in patients who receive transfusions may be humoral. Another study 
suggested that adenine and some unknown factors in the liquid or plasma portion of stored 
blood contributed to the inhibition of a normal lymphocytic proliferative response.' 
The study by Busch et al. lends support to the theory that factors generated during the 
storage and processing of blood are responsible for the immunologic sequelae of 
perioperative blood transfusion in patients with cancer. 
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N. Blumberg, M.D. 
University of Rochester, Medical Center, Rochester, NY 14642, U.S.A. 
J.M. Heal, M.R.C.P. 
American Red Cross, Blood Services, Rochester, NY 14607, U.S.A. 
To the Editor: 
Busch et al. found that the use of autologous blood as compared with allogeneic blood for 
transfusion does not improve the prognosis of patients with colorectal cancer. Few details 
are presented on the number of patients receiving a given dose of autologous or allogeneic 
blood or other components. No details are provided on the receipt of blood components 
such as fresh~frozen plasma, platelets. and albumin, nor was it revealed whether such 
components were autologous or allogeneic. Does the group of recipients of autologous 
transfusions mentioned in Table 4 of the article include patients who received allogeneic 
plasma, platelets, or albumin? 
We also wonder whether allogeneic red-cell transfusions were leukocyte-depleted in any 
manner at the blood center or hospital. Buffy-coat depletion is commonly used by the 
Dutch Red Cross, which supplies allogeneic blood to 14 of the 15 hospitals in the study. 
Leukocytes are suspected to be mediators of transfusion-induced immunomodulation on 
the basis of studies of renal-transplant recipients and of animals."? Leukocyte-depleted 
blood may diminish any inununosuppressive effect of transfusions. 
Did the authors investigate the total transfused dose of various allogeneic or autologous 
components as a prognostic factor in tumor recurrence, given that the dose is a strong 
predictor in outcome? The administration of one to two units of allogeneic red cells alone 
may be insufficient to render a transfusion effect readily detectable.' 
Another study of autologous transfusion and cancer recurrence is cited in the discussion as 
supporting the conclusions of this study.' The citation is to an abstract in which the 
authors conclude "blood transfusions have a relevant impact on recurrence rates in 
colorectal tumor patients." This reference appears to be cited in contradiction to its actual 
conclusions. The effect of transfusion on tumor recurrence remains an open question. 
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O.R.C. Busch, M.D., R.L. Marquet, Ph.D., w.e.J. Hop, M.Sc. J. Jeekel, Ph.D. 
University Hospital Dijkzigt, NL-3015 GD Rotterdam, The Netherlands 
To the Editor: 
Prognosis 
We agree with Ross that autologous blood transfusions may induce the same deleterious 
effects as allogeneic transfusions. This should be considered as an alternative explanation 
for a noncausal relation between blood transfusions and prognosis in colorectal cancer. 
However, as we discussed in our paper, in several studies in animals, including our 
own,1O syngeneic transfusions did not enhance tumor growth, whereas allogeneic 
transfusions did. It is interesting to consider the possibility that humoral factors in fresh-
frozen plasma have an effect similar to that of blood transfusions. In our study, the 
number of patients who received allogeneic fresh-frozen plasma was too small to permit 
reliable conclusions about their prognostic impact. In the group of patients who received 
autologous blood transfusions, nearly half also received autologous plasma, whereas none 
received allogeneic plasma. In the group of patients who received one or two allogeneic 
transfusions, 9 received fresh-frozen plasma, whereas 66 did not. The rates of disease-free 
survival at 4 years were 69% in the former group and 58% in the latter (p=0.70). Of the 
patients who did not need transfusions, 129 received no plasma, 9 received allogeneic 
plasma, and 5 received autologous plasma. The rates of disease-free survival in these three 
groups at 4 years were 75%, 89%, and 40%, respectively (p=0.75). 
Blumberg and Heal ask about possible dose effects of transfusions. We found no relation 
between the rate of recurrence of colorectal cancer and the number of transfusions. II In 
response to the argument that the transfusion of one to two units alone might be 
insufficient to have an effect, we found a transfusion effect of the same magnitude as the 
effect reported in a recent meta-analysis. 12 
The blood products used in our study were buffy-coat depleted, but not extra depleted of 
leukocytes. Such products could indeed overcome the detrimental effects of standard 
allogeneic transfusions whenever such effects exist. 
We think that the study by Heiss et al.' supports our conclusions. The outcomes, as shown 
in life-table analyses (unfortunately not presented in their abstract but presented at 
conferences), were similar to those we reported. 
Finally, we would like to emphasize that we performed a clinical trial that was not 
designed to investigate which substances in blood could be responsible for the putative 
immunologic changes. 
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Chapter 3 
Summary 
Blood transfusions have been indicated as having an adverse effect on the prognosis of 
patients treated surgically for cancer. We carried out a randomized trial to investigate 
whether a predeposit autologous blood transfusion program improved prognosis in patients 
with colorectal cancer as compared to the current practice of allogeneic transfusion. This 
appeared not to be the case. However, the subgroup of untransfused patients had a 
significantly better disease-free survival as compared with transfused patients; 73% and 
59%, respectively (p=O.OOI). We found that the risk of recurrence was significantly 
increased for patients transfused with allogeneic, or with autologous, or with both types of 
blood, compared with those patients who did not require transfusions; relative recurrence 
rates were 2.3 (p=O.OOI), 1.8 (p=O.044), and 2.5 (p=O.009), respectively; these three rates 
did not differ significantly from each other. 
We conclude that it is not the blood transfusions themselves, but the circumstances that 
necessitate the transfusions that arc the real determinants of prognosis. 
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Introduction 
The inununosuppressive effect of blood transfusions has been clearly demonstrated in 
patients undergoing kidney transplantation. 1 Whether blood transfusions have a 
detrimental effect on the prognosis of patients operated for a malignancy has long been a 
matter of debate. Although a relationship between blood transfusions and poor prognosis 
in colorectal cancer patients has been found in many retrospective studies,2 conflicting 
results have been reported, too? The question remains whether blood transfusions in 
themselves have a detrimental effect, or whether the relationship is only coincidental.' 
Randomization between transfused and untransfused patients is not possible,s and so 
comparison between these groups will always be biased by patient selection.6 
We performed a prospective randomized trial to compare the effects of predeposit 
autologous blood transfusion with standard allogeneic blood transfusions on the prognosis 
of colorectal cancer. As reported recently, we did not find a difference in disease-free 
survival and survival between the two randomized groupS.1 The current study concerns a 
further analysis of this trial to determine whether the subgroup of untransfused patients has 
a different prognosis compared with the transfused group of patients. 
Patients and methods 
The material for this study was obtained from a randomized multicenter trial in which 
eligible patients were randomized equally into either the allogeneic or the autologous arm 
of the study. Patients were eligible if they were scheduled for a potentially curative 
resection of a colorectal carcinoma, and if they also fulfilled the criteria for autologous 
blood donation, as stated by the American Association of Blood Banks.' Patients in the 
autologous group were required to donate 450 ml of blood twice. The collected blood was 
separated into packed red cells and fresh-frozen plasma. All patients were operated by 
standard procedures and the rules for transfusion were standardized in both groups. 
Transfusion was allowed to be given when blood loss was more than 500 mI, or if the 
hemoglobin concentration dropped below 6.5 nunoV!. Operative specimens were staged 
according to the Turnbull modification' of the original Dukes' classification. Only patients 
who had a curative resection were taken into account for this study. 
A standard follow-up program was used (including history, physical examination, and 
laboratory tests) every three months during the first two years and every six months 
thereafter. Chest X-ray and colonoscopy were performed yearly, and ultrasonography of 
the liver was done twice a year the first three years and once a year thereafter. 
Characteristic changes at physical examination or on chest X-ray, ultrasonography or CT-
scan were accepted as evidence for recurrence. Metastatic or recurrent disease was 
confirmed by histologic or cytologic examination when possible. 
45 
Chapter 3 
Chi-square test and Mann-Whitney's test were used where appropriate. Cumulative 4 
years' survival and disease-free survival were calculated using the life-table method of 
Kaplan-Meier. 10 The log-rank test was used to compare differences in Kaplan-Meier 
estimates. The Cox proportional-hazards models were used to evaluate factors in 
multivariate analysis. II Two-sided p values SO.05 were considered statistically significant. 
Results 
A total of 423 patients with colorectal carcinoma were operated curatively. In the 
allogeneic group there were 216 patients and 207 in the autologous group. Patient 
characteristics did not differ significantly between the two groups. Comparisons between 
the patients receiving transfusions and those who did not are shown in Table 3.1. 
Table 3.1. Comparison between transfused and untransfused patients. 
Untransfused Transfused p value 
(N = t43) (N = 280) 
Age (years) 65 (33·88) 67 (3 t-88) 0.049 
Sex 
Male 85 (59%) 158 (56%) n,s. 
Female 58 (4t%) 122 (44%) 
Operation 
Right hemicolectomy 25 (17%) 22 (8%) <0.0001 
Transverse colectomy 4 (3%) 3 (3%) 
Left hemicolectomy 12 (8%) t7 (6%) 
Sigmoid resection 47 (33%) 40 (14%) 
Anterior resection 48 (34%) Its (42%) 
Abdominoperineal resection 6 (4%) 80 (29%) 
Subtotal colectomy t (t%) 
Dukes' classification 
A 41 (29%) 67 (24%) n.s, 
B 50 (35%) 1I5 (41%) 
C 52 (36%) 98 (35%) 
Histological differentiation 
Well 19 (13%) 43 (15%) n.s. 
Moderate III (78%) 203 (73%) 
Poor 13 (9%) 32 (1I%) 
Adjacent organ fixation 7 (5%) 25 (9%) n.s. 
Tumor size (cm) 4.0 (0.5-15.0) 4.4 (0.8-10.0) 0.018 
Blood loss (mI) 400 (100·1,500) 1I00 (100·11.500) <0.0001 
Continuous data are shown as medians with ranges in parentheses, and categorical data as numbers of 
patients with percentages in parentheses. 
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In the transfused group the patients were older, had larger tumors and the amount of blood 
loss was significantly greater. In addition, there were significantly more anterior resections 
and abdominoperineal resections in the transfused group compared with the untransfused 
group. 
In the untransfused group 24 out of 143 patients developed recurrent disease as compared 
with 81 out of the 280 patients in the transfused group. The disease-free survival at 4 
years was 73% in the untransfused group, and 59% in the transfused group (p=O.OOl) 
(Figure 3.1). 
Figure 3.1. Disease-free survival comparing untransfused with transfused patients. 
The disease-free survival at 4 years is 73% in the untransfused group and 59% in the 
transfused group (p=O.OOl). 
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In Cox regression analysis, allowing for various prognostic factors the Dukes' 
classification was a very strong prognostic factor (Table 3.2). Blood transfusion was also 
correlated with poor prognosis. Randomization, however, was not a predictor of prognosis. 
Table 3.2. Multivariate analysis of various factors with respect to disease-free survival 
of the patients who underwent curative surgery. 
Factor Relative 95% 
recurrence confidence 
rate interval 
Randomization 
Allogeneic group 1 
Autologous group 0.9 0.6 - 1.4 
Age . 1.0 1.0 - 1.0 
Sex 
Male 1 
Female 1.2 0.8 - 1.7 
Dukes' classification 
A 1 
B 3.8 1.6 - 9.1 
C 10.1 4.8 - 20.7 
Tumor size . 1.1 1.0 - 1.2 
Differentiation 
Well 1 
Moderate 1.2 0.6 - 2.5 
Poor 2.1 0.9 - 4.7 
Operation 
Intra-abdominal 1 
Rectal involvement 1.1 0.7 - 1.7 
Adjacent organ fixation 
No 1 
Yes 0.4 0.2 - 0.9 
Transfusions 
No 1 
Yes 2.1 1.3 - 3.5 
As compared to 1 year younger (age) or 1 em smaller (tumor size). 
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p value 
0.671 
0.848 
0.478 
0.003 
<0.001 
0.061 
0.550 
0.700 
0.671 
0.027 
0.004 
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The group of transfused patients was subdivided into those who received only allogeneic 
(N=136), only autologous (N=102) and those receiving both types of transfusions (N=42) 
(Figure 3.2). At 4 years the disease-free survival was 56%, 62%, and 66%, respectively 
(p=0.50). The recurrence rates of the different types of transfusions were all significantly 
elevated as compared with those of the untransfused patients in Cox regression analysis 
adjusting for Dukes' classification (Table 3.3). There was no difference between the 
relative recurrence rates for the different types of transfusions (p=0.49). 
Figure 3.2. Disease-free survival comparing untransfused patients with different types 
of transfused patients. 
The group of patients receiving only allogeneic transfusions (allo), only autologous 
transfusions (auto), and both types of transfusions (both) are all significantly (p=O.007) 
different from the untransfused patients (none). 
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Table 3,3, Multivariate analysis for Dukes' classification and transfusion status. 
Factor 
Dukes' classification 
A 
B 
C 
Transfusions 
None 
Allogeneic 
Only autologous 
Allogeneic and autologous 
Relative 
recurrence 
rate 
I 
3.8 
10.9 
I 
2.3' 
1.8' 
2.5' 
95% 
confidence 
interval 
1.6 - 9.1 
4.7 - 25.2 
1.4 - 3.8 
1.0 - 3.1 
1.3 - 4.8 
No significant difference between the three transfusion groups (p=0,49). 
Discussion 
p value 
0.002 
<0.001 
0.001 
0.044 
0.009 
This analysis shows that there is a relation between blood transfusions and disease-free 
survival in colorectal cancer patients. The relationship, however, is not likely to be causal, 
because the increased relative risk is about the same between those patients receiving 
allogeneic transfusions, those receiving only autologous transfusions, and those receiving 
both types of transfusions. 
As reported earlier, the implementalion of an aulologous blood dona lion program reduced 
the exposure to allogeneic blood considerably," but had no advantage in the prognosis of 
colorectal cancer patients.7 
Similarly, Tarller," in a prospective sludy, showed a significant difference between the 
untransfused and transfused patients; the 5 years' disease-free survival was 77% for 
untransfused patients and 57% for transfused patients. In a recent meta-analysis. 14 
including 20 relrospeclive studies representing over 5000 patients, a relationship between 
blood transfusions and poor prognosis of the same magnitude as our results was reported. 
The cumulative odds-ralio of the disease-free survival was 1.8. 
We conclude that blood transfusions are related to poor prognosis in colorectal cancer 
patients, but this relationship is not causal. Therefore, it is not the blood transfusions 
themselves but rather the circumstances that necessitate transfusion that are the real 
determinants of prognosis. 
50 
Impact all diseasejree survival 
References 
1. Opelz G, Sengar DPS, Mickey MR, Terasaki PI. Effect of blood transfusion on subsequent kidney 
transplants. Transplant Proc 1973; 5:253-9. 
2. Blumberg N, Heal JM. Transfusion and hosl defenses against cancer recurrence and infection. 
Transfusion 1989; 29:236-45. 
3. Francis DMA. Relationship between blood transfusion and tumour behaviour. Br J Surg 1991; 
78:1420-8. 
4. Brunson ME, Alexander JW. Mechanisms of transfusion-induced immunosuppression. Transfusion 
1990: 30:651-8. 
5. van Lawick van Pabst \VP, Langenhorst BLAM, Mulder PGH, Marquet RL, Jeekel J. Effect of 
perioperative blood loss and perioperative blood transfusion on colorectal cancer survival. Eur J 
Cancer Clin Oneal 1988; 24:741-7. 
6. Taylor RMR, Parrott NR. Red alert. Br J Surg 1988; 75:1049-50. 
7. Busch ORC, Hop weJ, Hoynck van Papendrecht MAW, Marquet RL, Jeekel J. Blood transfusions 
and prognosis in colorectal cancer. N Eng! J Med 1993; 328: 1372-6. 
8. Council on Scientific Affairs. Autologous blood transfusions. JAMA 1986; 256:2378-80. 
9. Turnbull RB, Kyle K, Watson FR, Spratt J. Cancer of the colon: The influence of the no-touch 
isolation technic on survival rates. Ann Surg 1967; 166:420-5. 
10. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 
1958: 53:457-81. 
11. Cox DR Regression models and life tables. J R Stat Soc [B] 1972; 34:187-202. 
12. Hoynck van Papendrecht MAW, Hop W, Langenhorst BLAM, Kothe FC, Marquet RL, Jeeke! J. 
Feasibility of a predeposit autologous blood donation program in colorecta! cancer patients: Results 
from a randomized clinical study. Vox Sang 1992; 62:102-7. 
13. Tartter PI. The association of perioperative blood transfusion with colorectal cancer recurrence. Ann 
Surg 1992: 216:633-8. 
14. Chung M, Steinmetz OK, Gordon PH. Perioperative blood transfusion and outcome after resection 
for colorectal carcinoma. Br J Surg 1993; 80:427-32. 
51 

CHAPTER 4 
BLOOD TRANSFUSIONS AND LOCAL TUMOR RECURRENCE IN 
COLORECTAL CANCER: EVIDENCE OF A NONCAUSAL RELATIONSIDP 
O.R.C. Busch, W.C.J. Hop, R.L. Marquet, J. Jeekel. 
Published in: 
Annals of Surgery 1994; 220: 791-797. 
Chapter 4 
Summary 
Retrospective studies suggest that blood transfusions are associated with a poor prognosis 
in patients who undergo operations for caloTectal malignancies. In a previously published, 
randomized trial, it was investigated whether autologous blood transfusions could 
overcome this putative detrimental effect. However, this did not appear to be the case. In 
the current study we analyzed the patterns of recurrence in 420 patients who underwent 
curative operations for colorectal cancer. Patients who did not require transfusions 
(N=143) had significantly better disease-free survival than those who did need transfusions 
(N=277); percentages at 4 years were 73% and 59%, respectively (p=O.OOI). No difference 
was found between both groups in comparing cumulative percentages of patients having 
metastases; percentages at 4 years were 25% in the group that did not undergo transfusion 
and 27% in the transfused group. The percentage of cases having local recurrence, 
however, was significantly increased (p=0.0006) in the transfused group as compared with 
the group that did not undergo transfusion; percentages at 4 years were 20% and 3%, 
respectively. The groups of patients receiving only allogeneic, only autologous, or both 
types of transfusions all had a significantly higher incidence of local recurrence than the 
patients who did not receive transfusions, but no differences were found between these 
three groups. These findings suggest that the association between blood transfusions and 
prognosis in colorectal cancer is a result of the circumstances that necessitate transfusions, 
leading to the development of local recurrences but not of distant metastases. 
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Introduction 
It has been suggested that allogeneic blood transfusions are associated with a poor 
prognosis of patients who undergo operations for colorectal cancer, possibly because of 
immunologic factors. I•2•3•4 A recent meta~analysis, combining the evidence of 20 
published retrospective studies, demonstrated that transfused patients with colorectal 
cancer generally had a worse progllOsis when compared with patients who did not undergo 
transfusion,s However, in a randomized trial of 475 patients, we did not find that patients 
transfused with autologous blood had a better prognosis than those patients transfused with 
allogeneic blood, although transfused patients, receiving either type of blood, had a poorer 
prognosis than patients who did not receive transfusions.6 Therefore, the circumstances 
necessitating transfusions rather than the blood transfusions themselves are the real 
determinant of prognosis. Naturally, the need for postoperative transfusions was associated 
with the amount of blood loss. This might be related to technical difficulties to resect the 
tumor, and to surgical skill.' These factors also may affect the development of local 
recurrence. because local recurrences originate from remaining viable local tumor 
residues,8 or local spill.9 Previous studies reporting on the effects of blood transfusions 
on prognosis presented data on survival or disease-free survival. However, in only a few 
studies the incidence of local recurrence and metastatic disease was evaluated separately, 
but did not come to conclusions. ln In the current study, the relationship between blood 
transfusions and the patterns of recurrent disease in patients participating in the 
aforementioned trial was investigated. 
Methods 
Those evaluated were patients who underwent curative operations and participated in a 
randomized, multicenter trial to investigate the effect of autologous blood on prognosis of 
colorectal cancer as compared with standard allogeneic transfusions. The design of this 
trial has been described in detail elsewhere.6 Briefly, patients with a potentially curative 
resection of a colorectal carcinoma were eligible if they fulfilled the criteria set for 
autologous blood donation." Patients randomized into the autologous group had to 
donate two units of blood in two sessions before operation. The collected blood was 
separated into packed red cells and fresh-frozen plasma. The transfusion rules were the 
same for patients in the autologous group as for patients in the allogeneic group. Packed 
red cells were allowed to be given if blood loss exceeded 500 ml or if the hemoglobin 
level dropped below 10.5 gld!. 
After standard surgical procedures, the tumors were staged according to the TurnbuH I2 
modification of the original Dukes' classification. A tumor confined to the bowel wall was 
staged as Dukes' A; if the tumor extended through the serosa into the pericolic fat, it was 
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staged as Dukes' B: and if regional lymph nodes contained metastases, it was staged as 
Dukes' C. En bloc resected tumors with adjacent organ fixation were not staged as Dukes' 
D. No adjuvant chemotherapy was given, and pelvic radiation was only given in a 
minority of cases. 
A standard follow-up program was used, including history, physical examination, and 
laboratory tests, every three months during the first two years and every six months 
thereafter. Chest X-ray and colonoscopy were performed yearly, and ultrasonography of 
the liver was done twice a year for the first three years and once a year thereafter. 
If possible, histologic or cytologic evidence was obtained to confirm metastatic or local 
recurrent disease. Characteristic changes at physical examination, on X-ray, on liver 
ultrasonography. or on computer tomography scan also were accepted as metastatic disease 
Of as local recurrence. 
In this study, the incidence of distant metastases and local recurrence were analyzed as 
first signs of recurrent disease. Of the 475 randomized patients, 423 patients underwent 
curative surgery. Three of these patients died from postoperative complications. The 
remaining 420 patients form the basis of this report. 
Incidences implicating cumulative percentages of patients having metastases and 
cumulative percentages of patients having local recurrences were calculated according to 
the Kaplan-Meier method.13 The log-rank test was used to compare these estimates. 
Multivariate analyses were performed using Cox regression. 14 Two~sided p value ::;0.05 
was considered the limit of statistical significance. 
Results 
Patient characteristics 
Of the 420 patients, 214 patients belonged to the allogeneic group and 206 to the 
autologous group. The median follow-up period of the patients was 2.3 years (range, I to 
59 months). No patient was lost to follow-up. 
Of the 420 patients, 277 received transfusions and 143 patients did not. Of these 277 
patients, 134. received only allogeneic transfusions, 101 received only autologous 
transfusions, and 42 patients received both types of transfusions. 
Recurrent disease 
For all studied patients (i.e., whether they received transfusions or not) the disease-free 
survival at 4 years was 66% in the allogeneic group and 63% in the autologous group 
(p:0.93). In the allogeneic group, 54 of 214 patients developed recurrent disease (39 
distant metastases, 13 local 'recurrences and two patients both simultaneously). In the 
autologous group, 51 of 206 patients developed recurrent disease (30 distant metastases, 
20 local recurrences and one patient both). The distribution of sites of recurrent disease 
per randomized group is shown in Table 4.1. 
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Table 4.1. First detected site of recurrent disease according to randomized group. 
Allogeneic group Autologous group 
(N = 2(4) (N = 206) 
Total 54 51 
Local recurrence 13 20 
Metastatic disease 39 30 
Liver 23 (59%) 17 (57%) 
Lung 5 (13%) 2 (7%) 
Brains 2 (5%) 
Other 3 (8%) 5 (16%) 
Multiple 6 (15%) 6 (20%) 
Local and metastatic disease 2 
Figure 4.1. Cumulative percentages of palients having distant metastases according to 
transfusions received. 
The group of patients receiving only allogeneic transfusions (allo), only autologous 
transfusions (auto), and both types of transfusions (both) are all not significantly different 
from the untransfused patients (none). 
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The disease-free survival at 4 years was 59% in the group of 277 patients who received 
transfusions versus 73% in the group of 143 patients who did not require transfusions 
(p=O.OOI). Using multivariate analysis, allowing for various prognostic factors, blood 
transfusion was a significant determinant of disease-free survival.'5 
Table 4.2. Characteristics of patients with metastatic disease and with local recurrence. 
Total Metastatic disease Local recurrence 
Randomization 
Allogeneic group 214 39 (41) 13 (15) 
Autologous group 206 30 (31) 20 (21) 
Age (years) 67 67 (67) 66 (66) 
Sex 
Male 242 39 (42) 12 (15) 
Female 178 30 (30) 21 (21) 
Operation 
Intra-abdominal 171 30 (30) 7 (7) 
Rectal involvement 249 39 (42) 26 (29) 
Dukes' classification 
A 107 2 (2) 4 (4) 
B 165 23 (24) 13 (14) 
C 148 44 (46) 16 (18) 
Histological differentiation 
Well 62 6 (7) 2 (3) 
Moderate 311 47 (49) 27 (29) 
Poor 45 16 (16) 4 (4) 
Tumor size (em) 4 4 (4) 5 (5) 
Adjacent organ fixation 32 4 (4) 3 (3) 
Adjuvant irradiation 31 II (12) 5 (6) 
Blood loss (ml) 750 900 (900) 1300 (1300) 
Blood transfusions 
No 143 21 (21) 3 (3) 
Yes 277 48 (51) 30 (33) 
Continuous data are presented as medians and categorical data as numbers of patients. 
Adding those patients with both metastatic disease and local recurrence are shown in parentheses. 
The characteristics of the patients with metastatic disease and those with local recurrences 
are shown in Table 4.2, and the univariate evaluations of different prognoslic factors are 
reported in Table 4.3. No statistically significant differences were found in Ihe cumulative 
percentages of distant metastases and of local recurrence in comparing the randomized 
groups. The Dukes' classification was a significant prognostic factor for both end points. 
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The grade of differentiation also was a significant factor for the incidence of metastases, 
but in Cox regression analysis, allowing for Dukes' stage, this was not the case. 
Involvement of the rectum, blood loss, and blood transfusions each were related 
significantly with the incidence of local recurrence, but not with the incidence of 
metastatic disease (Table 4.3). 
Table 4.3. Univariate comparisons of patients having distant metastases and those 
having local recurrence according to various factors. 
Metastases log-rank Local log-rank 
p value recurrence . p value 
Randomization 
Allogeneic group 27% n.s. 11% n.s. 
Autologous group 25% 17% 
Age (years) 
~ 65 27% n.s. 13% n.s. 
> 65 27% 14% 
Sex 
Male 29% n.s. 12% n.s. 
Female 22% 16% 
Operation 
Intra-abdominal 27% n.s. 7% 0.007 
Rectal involvement 25% 19% 
Dukes' classification 
A 2% <0.0001 7% 0.004 
B 23% 10% 
C 49% 27% 
Differentiation 
Well 20% 0.0006 7% n.s. 
Moderate 24% 14% 
Poor 49% 25% 
Tumor size (cm) 
<5 26% n.s. 13% n.s. 
~5 26% 16% 
Adjacent organ fixation 
No 27% n.s. 14% n.s. 
Yes 13% 8% 
Blood loss (ml) 
~500 23% n.s. 4% 0.00 1 
> 500 and ~ 1000 28% 14% 
>1000 28% 24% 
Blood transfusions 
No 25% n.s. 3% 0.0006 
Yes 27% 20% 
Cumulative percentages at 4 years, according to Kaplan-Meier estimates. 
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Cumulative percentages of metastases comparing the patients who did not undergo 
transfusion and the transfused patients is shown in Figure 4.1. The percentage of 
metastases at 4 years was 25% in the group of patients who did not undergo transfusion 
and 27% in the transfused group. The percentages of metastases did not differ significantly 
between the different types of transfusions; at 4 years, the cumulative percentage of 
metastases in the group of patients receiving only allogeneic transfusions (N~134), only 
autologous transfusions (N~lOl) or both types of blood transfusions (N~42) were 31%, 
33%, and 14%, respectively. 
Figure 4.2. Cumulative percentages of patients having local recurrence according to 
transfusions received. 
The group of patients receiving only allogeneic transfusions (allo), only autologous 
transfusions (auto), and both types of transfusions (both) are all significantly different 
from the untransfused patients (none). 
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However, the cumulative percentage of local recurrence was significantly less in the group 
of patient who did not undergo transfusion as compared with the groups of patients with 
different types of transfusions (Figure 4.2). The percentage of local recurrence was 3% in 
the group that did not undergo transfusion and 20% in the transfused group (p=0.OO06). 
The cumulative percentages of local recurrence at 4 years in the group of patients 
receiving only allogeneic transfusions, only autologous transfusions, or both types of blood 
transfusions were 20%, 18%, and 23%, respectively, and all were significantly higher than 
the group that did not undergo transfusion (p=O.OOl, p=0.02, and p<O.OOl, respectively). 
The percentages of local recurrence of these three transfused groups of patients did not 
significantly differ between each other (p=0.18). 
Multivariate analyses. not allowing for blood loss, showed that blood transfusion was a 
significant determinant for local recurrences. This was not the case for metastases (Table 
4.4). When postoperative radiation, given in a minority of cases (Table 4.2), also was 
taken into account in these regression models, the estimates and p values did not change 
appreciably, and irradiation was not an additional prognostic factor. When blood loss in 
the multivariate analysis was taken into consideration, the impact of blood transfusions on 
the local recurrence rate was no longer statistically significant (Table 4.4). 
To explore the effect on prognosis of preoperative autologous donation itself, only the 
patients who did not undergo transfusion were evaluated. Comparison of those patients in 
the allogeneic group (N=94) with those in the autologous group (N=49) showed no 
significant differences in disease-free survival (75% versus 69%), percentage of distant 
metastases (23% versus 29%), and percentage of local recurrence (3% versus 2%). 
Table 4.4. Multivariate analysis of the incidence of metastases and local recurrence. 
Factor 
Blood transfusions 
No 
Yes 
Dukes' stage 
A 
B 
C 
Operation 
Intra*abdominal 
Rectal involvement 
Relative 
metastases 
rate 
1 
1.6 
1 
7.6 
23.8 
1 
1.0 
p value Relative local p value 
recurrence 
rate 
n.s. 5.2' 0.008 
1 
0.006 2.2 n.s. 
<0.001 5.1 0.004 
1 
n.s. 2.0 n.s. 
This estimate is 3.5 (p=O.06) when in the analysis also blood loss was taken into account (relative 
local recurrence rate equals 1.3 as compared with 50% lower amount of blood loss; p=O.14). The 
addition of blood loss did not appreciably change the other estimates or their p values. 
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Discussion 
Blood transfusions seem to be associated with poor prognosis of colorectal cancer. This 
relationship appeared not to be causal; rather, the circumstances that necessitate 
transfusions are of prognostic importance in colorectal cancer patients.' Of all studies 
reporting on recurrent disease from colorectal cancer and blood transfusions, only a few 
made a distinction between local recurrence and metastatic disease in the analyses. So far, 
no additional information has been given about the negative association between blood 
transfusions and prognosis. 
The current study shows that the relationship between blood transfusions and the increased 
risk of recurrent disease is a result of an increased risk of local recurrences. No relation 
was found with the incidence of distant metastases. Similar findings applied to the amount 
of blood loss, but evaluating blood loss and transfusions simultaneously by multivariate 
analysis made the significance of either factor disappear. This is a consequence of the 
strong relationship that existed between blood loss and transfusion because of our 
transfusion rules (median blood loss in case of no transfusion was 400 rul and in case of 
transfusion 1100 ml; p<O.OOI). The only other prognostic factor affecting local recurrence 
and not metastatic disease was an operation of a rectal tumor, compared with an intra-
abdominal tumor. Although resections of rectal tumors are associated with larger amounts 
of blood loss and therefore, require more transfusions, multivariate analysis showed blood 
transfusion to be an independent factor of prognosis. In addition, there are studies 
restricted to colonic cancer that found a detrimental effect of blood transfusions, toO. 16.17 
In the current study, we found that the influence of rectal involvement was not additional 
to the effect of blood transfusions in multivariate analysis. In our patient population, the 
incidence of rectal involvement was relatively high, which is caused by our inclusion 
criteria. All patients should be able to donate blood and therefore, must have a hemoglobin 
level of at least 11.3 gldl (7 mmolll). Patients with tumors in the right colon often have 
had anemia or transfusions preoperatively and are (in both situations) ineligible for our 
study. 
In this study, only three patients had both local recurrence and metastatic disease at the 
moment recurrent disease was diagnosed. In retrospective studies, this number usually was 
higher, which probably can be explained by the prospective design of our study and our 
intensive follow-up program, in which examinations such as liver ultrasonography were 
performed routinely. 
From the moment recurrent disease was detected, the median survival time was similar in 
patients who had local recurrences and those who had distant metastases. Thus, a 
detrimental prognostic relationship between transfusions and the development of local 
recurrence will have a comparable effect on survival. The retrospective studies reporting 
on the effect of blood transfusions and cancer survival might, therefore, be explained by a 
deleterious relationship of transfusions and local recurrence only. 
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A recent prospective study by Tartter l ' found a transfusion effect on the disease-free 
survival of colorectal cancer patients. The 5 years' disease-free survival was 77% for 
patients who did not undergo transfusion and 57% for transfused patients. In a recent 
meta-analysis,' representing over 5000 patients, a relationship between blood transfusions 
and poor prognosis was reported of the same magnitude as found in our study. 
Unfortunately, in those studies, there were no data available on the incidence of local 
recurrence and the incidence of metastatic disease separately. 
The fact that local recurrence represents failure of the surgical technique is demonstrated 
by McArdle and Hole,19 who reported on the variability among surgeons on postoperative 
complications and ultimate survival. It has been suggested that a more meticulous and 
careful dissection of the pararectal tissues reduc(+S the incidence of local recurrence for 
rectal tumors.20 Recently, the results of total mesorectal excision for rectal cancer were 
reported and showed that such surgery gave better disease-free survival than other studies 
had demonstrated using adjuvant radiation or chemotherapy?I,22 
Another explanation of the current findings might be the presence of growth factors 
released from platelets after blood loss in the peritoneal cavity. An enhanced peritoneal 
tumor load was found in rats receiving serum intraperitoneally as compared with those that 
did not receive it.23 However, the rate of liver metastases also was increased in this 
animal model. 
The current study shows that the prognostic association between blood transfusions and 
colorectal cancer is mainly a result of the an increased risk of local recurrences and not an 
increased risk of metastatic disease. Assuming that local recurrence and the need for blood 
transfusions are related to surgical difficulties and skill, operations all patients with 
colorectal cancer should be performed in a meticulous way, with precise tumor excision 
and as few transfusions as necessary. 
Therefore, patients who are scheduled for potentially curative resections of colorectal 
malignancies may have better prognoses if their surgeries are performed by surgeons who 
are experienced in colorectal cancer surgery. 
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Summary 
In several studies it was suggested that blood transfusions may have a detrimental effect 
on the susceptibility to infectious complications after surgery. So far no large clinical 
study investigated this issue in a randomized setting. We analyzed the postoperative 
infectious complications of 470 patients who were operated for colorectal cancer and who 
had been randomized to receive allogeneic or autologous blood transfusions if required. 
The objective was to determine in a randomized multicenter clinical trial, whether 
predeposit autologous blood transfusions can decrease the incidence of postoperative 
infections. In the allogeneic group 58 of the 234 patients (25%) and in the autologous 
group 64 of the 236 patients (27%) had postoperative infectious complications (p=0.64). 
Regression analysis showed that tumor location, age and blood transfusion were significant 
risk factors for infections. Patients who received more than two units of blood had a 
significantly increased risk of infections, irrespective of the type of transfusions received, 
whereas patients receiving up to two transfusions had the same rate of infections as those 
patients who did not need transfusions. The odds-ratio for infections was 2.0 (95% 
confidence interval, 1.0 to 3.9; p<O.OOI) for patients receiving more than two allogeneic 
transfusions and 3.6 (95% confidence interval, 1.8 to 7.3; p<0.05) for patients receiving 
autologous and allogeneic transfusions. These two ratios were not significantly different 
from each other (p=0.14). We conclude that a predeposit autologous blood transfusion 
program does not decrease the risk of infectious complications after colorectal cancer 
surgery. We further believe that our finding of an increased risk of infections in case a 
large number of transfusions is given, is not due to the blood transfusions themselves, but 
rather the circumstances necessitating them. 
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Introduction 
Several studies on the ~jsk of infectious complications after colorectal cancer surgery have 
found that the incidence of postoperative bacterial infections is increased when patients 
were transfused. I ,2.3 The immunological changes induced by perioperative allogeneic 
blood transfusions are held responsible for this increased susceptibility to infections.4.5 
Obviously, blood transfusions are not the only immunomodulatory factors in the 
peri operative period. Also anesthesia, blood loss and surgical stress may influence the 
patients immune status. However most studies have found that after correcting for various 
risk factors of infections, by using multivariate analysis, blood transfusion was an 
independent factor.6 Unfortunately, the causality of the factor blood transfusion is 
impossible to investigate properly in uncontrolled studies. The need for transfusion might 
be related to factors which are unknown or difficult to quantify and therefore unable to 
properly allow for. Surgical difficulty and skill could be related to both the need for blood 
transfusions and postoperative infectious complications. One of the options to overcome 
the possible detrimental effects of transfusions is the use of predeposit autologous blood, 
because no immunological changes induced by autologous transfusions have been reported 
so far. 
We have performed a randomized multicenter study to compare the effects of allogeneic 
and autologous blood transfusions on prognosis and infectious complications after 
colorectal cancer surgery. The results on cancer prognosis have been published recently.7 
The present paper reports on the relationship between the different types of blood 
transfusions and postoperative infectious complications observed in this randomized 
clinical trial. 
Methods 
Patients who were scheduled for a curative resection of a colorectal carcinoma were 
eligible for the study if they fulfilled the criteria set for autologous blood donation.' 
Between August 1986 and November 1991, eligible patients in the 15 participating 
hospitals were randomly assigned either to the allogeneic group or to the autologous 
group. The randomization procedure included stratification per hospital. Patients 
randomized to the autologous group were required to donate two units of blood prior to 
surgery. These units of blood were separated into packed red cells (without buffy-coat) 
and fresh-frozen plasma. If needed according to our transfusion rules, blood loss over 500 
ml or a hemoglobin concentration drop below 10.5 gldl (6.5 mmol!l), the packed red cells 
were transfused. In the allogeneic group third party blood transfusions were given if 
necessary regarding the same rules for transfusion. The design of this trial has been 
described in more detail elsewhere.7 
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Bowel irrigation and antibiotic prophylaxis were given routinely in each hospital. 
Postoperative infectious complications were scored by the responsible surgeon. Wound 
infections were defined as drainage of pus from the wound, urinary tract infections as 
positive urine culture with clinical signs, pneumonia as positive sputum culture with 
specific clinical signs or changes on chest X-ray. Intra-abdominal infections were those 
found during laparotomy or abscesses which were drained transcutaneously by using 
ultrasonography or CT-scan. 
A total of 475 patients were randomized in this trial. Five patients (two in the allogeneic 
group and three in the autologous group) were not operated after randomization and were 
excluded from the analysis. 
Percentages were compared by the chi-square test (with Yates' correction in case of 2 by 
2 tables). Tests for trend were performed when appropriate. Logistic regression9 was used 
to investigate various factors simultaneously regarding the incidence of infectious 
complications. Exact 95% confidence limits of odds-ratios were determined using the 
program EGRET. 1O Two-sided p value ';0.05 was considered statistically significant. 
Results 
The characteristics of the 470 patients operated for colorectal carcinoma were not greatly 
different comparing the two randomized groups (Table 5.1). 
Eight patients (three in the allogeneic group and five in the autologous group) died of 
postoperative complications. In the allogeneic group 58 out of the 234 patients (25%) had 
postoperative infectious complications as compared with 64 of the 236 patients in the 
autologous group (27%). These percentages did not differ significantly from each other 
(p=O.64). 
To investigate the influence of the multicentricity of our study we calculated the odds-
ratios (autologous versus allogeneic randomized group) for infectious complications per 
hospital (Figure 5.1). By analyzing this hospital effect it was found that there was no 
significant difference (p=0.97) in odds-ratios for the 15 participating hospitals. The 
common odds-ratio for infections was 1.2 (95% confidence interval, 0.8 to 1.9), which did 
not differ significantly (p=0.49) from 1, i.e. the value indicating no difference between 
both randomized groups. Logistic regression analysis. including age and tumor location. 
was performed to obtain a higher level of precision in the comparison of the randomized 
groups. The adjusted odds-ratio for the risk of infectious complications in the autologous 
versus the allogeneic group was 1.2 (95% confidence interval, 0.8 to 1.8; p=0.48). 
Comparing the different sites of infectious complications also did not show a significant 
difference between the two randomized groups (Table 5.2). 
Univariate analyses regarding possible influencing factors are shown in Table 5.3. 
Location of the tumor in the rectum, and the age of the patient were the most important 
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factors associated with the risk of infections. Also blood loss and transfusions of fresh-
frozen plasma were factors which were significantly related to the risk of infections, 
whereas blood transfusions (red cells) did not affect the infection rate. The group of 
patients receiving blood transfusions of any type had infections in 29% of the cases as 
compared with 21 % in the group of patients who did not receive transfusions (p=0.084). 
However, when the group of patients who received transfusions were subdivided in 
different types of transfusions a significant difference for the rate of infectious 
complications appeared (p<O.OOOI). Transfusion of more than two units of blood increased 
the risk of infections markedly whereas the first two transfusions did not. Rates of 
infections were 21%, 19%, and 19% for the patients without transfusions, one or two 
allogeneic transfusions, and one or two autologous transfusions, respectively. The patients 
receiving more than two allogeneic transfusions had in 40% of the cases infectious 
complications and the patients receiving allogeneic units additional to the autologous 
transfusions in 53% of the cases. 
FIgure 5.1. Odds-ratios for infectious complications (autologous versus allogeneic 
group) per hospital. Hospitals are arranged in order of increasing odds-ratio. 
Significance of difference of odds-ratios; p=0.97. Common odds-ratio equals 1.2 (95% 
confidence interval. 0.8 to 1.9; p=0.49). 
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Table 5.1. Characteristics of the patients who were operated for colorectal cancer per 
randomized group. 
Allogeneic group Autologous group 
(N = 234) (N = 236) 
Age (years) 68 (33·89) 66 (31-88) 
Sex 
Male 131 (56%) 141 (60%) 
Female 103 (44%) 95 (40%) 
Operation 
No resection 2 (1%) 5 (2%) 
Right hemicolectomy 30 (13%) 23 (10%) 
Transverse colectomy 2 (1%) 5 (2%) 
Left hemicolectomy 15 (6%) 16 (7%) 
Sigmoid resection 45 (19%) 50 (21%) 
Anterior resection 92 (39%) 87 (37%) 
Abdominoperineal resection 47 (20%) 50 (21%) 
Total colectomy I (1%) 
Dukes' classification 
A 53 (23%) 55 (23%) 
B S5 (36%) 80 (34%) 
C 78 (33%) 72 (31%) 
D IS (8%) 29 (12%) 
Histological differentiation 
Well 35 (15%) 33 (14%) 
Moderate 169 (73%) 172 (74%) 
Poor 28 (12%) 29 (12%) 
Adjacent organ fixation 20 (9%) 26 (11%) 
Tumor size (em) 4.3 (0.5-13.0) 4.0 (0.8-15.0) 
Hemoglobin concentration 14.5 (1O.5-IS.O) 14.4 (l1.I-IS.5) 
at base-line (gldl) 
Blood loss (ml) 775 (100-11,500) 750 (100-6.500) 
Continuous data are presented as medians with ranges in parentheses and categorical data as numbers of 
patients with percentages in parentheses, 
Table 5.2, Postoperalive infectious complications after colorectal surgery. 
Allogeneic group Autologous group 
(N = 234) (N = 236) 
Infections 58 (25%) 64 (27%) 
Wound 14 (6%) 22 (9%) 
Intra-abdominal 12 (5%) 18 (S%) 
Urinary tract 19 (S%) 15 (6%) 
Pneumonia S (3%) 6 (3%) 
Other 5 (2%) 3 (1%) 
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Table 5.3. Univariate analysis of various risk factors of infectious complications. 
Total Infections p value (trend) 
Randomization 
Allogeneic group 234 58 (25%) 0.64 
Autologous group 236 64 (27%) 
Age (years) 
~60 129 20 (16%) 0.004 (0.027) 
61 - 70 172 55 (32%) 
> 70 169 47 (28%) 
Sex 
Male 272 69 (25%) 0.81 
Female 198 53 (27%) 
Operation 
Intra-abdominal 202 39 (19%) 0.006 
Rectal involvement 268 83 (31%) 
Dukes' classification 
A 108 33 (31%) 0.64 (0.48) 
B 165 39 (24%) 
C 150 38 (25%) 
D 47 12 (26%) 
Adjacent organ ftxation 
No 424 106 (25%) 0.21 
Yes 46 16 (35%) 
Tumor size (em) 
s3 108 27 (25%) 0.89 (0.68) 
3 - 5 161 40 (25%) 
~5 186 50 (27%) 
Base-line hemoglobin level (gfdl) 
~ 13.7 171 41 (24%) 0.68 (0.39) 
13.8 - 15.3 182 49 (27%) 
> 15.3 98 28 (29%) 
Blood loss (ml) 
~ 500 154 31 (20%) 0.025 (0.010) 
501 - 1000 138 31 (22%) 
>1000 159 52 (33%) 
Plasma transfusions 
None 341 78 (23%) 0.038 
Allogeneic 57 21 (37%) 
Autologous 72 23 (32%) 
Blood transfusions 
None 159 33 (21%) < 0.0001 
Allogeneic, 1 or 2 units 88 17 (19%) 
Autologous, 1 or 2 units 112 21 (19%) 
Allogeneic, > 2 units 62 25 (40%) 
Autologous and allogeneic 49 26 (53%) 
Note: Due to some missing data the lotal number of patients does not always equal 470. 
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In the allogeneic group 21 of the WI patients who did not receive transfusions (21%) had 
infectious complications. The same percentage (12 of the 58 patients) was obtained in the 
patients who did not receive transfusions in the autologous group. 
In Table 5.4 the risk of infectious complications is shown for the different groups of 
transfusions when taking into account the tumor location and the age of the patient. It was 
found that the group of patients receiving onc or two allogeneic transfusions and the group 
receiving one or two autologous transfusions had a comparable risk of infectious 
complications as those patients who did not receive any transfusion. However, the patients 
who needed more than two units of blood had an increased risk of infections. This was the 
case in the allogeneic group (more than two units) and in the autologous group when 
additional allogeneic transfusions were given. Therefore more than two transfusions 
increased the risk of infectious complications. There was no significant difference whether 
the first two transfusions were of the allogeneic or autologous type. Plasma transfusion 
and blood loss, which were significantly related to infections when considered 
univariately, were no statistically significant additional influencing factors regarding the 
incidence of infectious complications in this regression analysis. 
Table 5.4. Logistic regression analysis of various factors affecting the risk of infectious 
complications. 
Infections Odds-ratio 95% C.I. P value 
Blood transfusions 
None 21% 1 
Allogeneic, 1 or 2 units t9% 0.7 0.4 - 1.4 0.35 
Autologous, I or 2 units 19% 0.8 0.4 - L4 0.42 
Allogeneic, > 2 units 40% 2.0' LO - 3.9 < O.OOt 
Autologous and allogeneic 53% 3.6' L8 - 7.3 0.047 
Tumor location 
Intra-abdominal 19% t 
Rectal involvement 31% L7 LO - 2.7 0.036 
Age (years) 
~ 60 16% t 
6t -70 32% 2.6 L4 - 4.7 0.002 
> 70 28% 2.1 L2 - 3.9 0.Ql5 
Not significantly different from each other (2.0 versus 3.6; p=O.14). 
Discussion 
This study shows that there is no beneficial effect of using autologous blood instead of 
allogeneic blood to reduce postoperative infectious complications in colorectal cancer 
patients. Heiss et a1." reported' a randomized study similar to the present study. and 
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found that patients who were randomized to the autologous group had less infections. 
However, this study included only a total of 120 patients, and their finding was of 
marginal statistical significance. Also, they did not find a significant difference when the 
transfused patients of both randomized groups were compared. 
We have previously shown that the donation of two units of blood had a significant effect 
on the immunological status of the patient." However, the finding that the rate of 
infections of the patients who did not receive transfusions in both randomized groups were 
the same (21 %), suggests that these changes do not affect the rate of infectious 
complications. 
The other studies comparing the effect of allogeneic and autologous blood transfusions 
were uncontrolled. 13 Mezrow et at 14 described a group of patients who underwent 
various surgical procedures. including a few colorectal cancer patients. and found that the 
infectious complication rate in the autologous recipients was reduced as compared to 
allogeneic recipients. However, the patients receiving autologous blood had shorter 
procedures, less blood loss, and needed fewer transfusions. Therefore, their findings were 
probably biased by imbalances between patients who underwent predeposit autologous 
donation and patients who did not. The study by Murphy et al.1S found an advantage of 
autologous transfusions in patients who underwent total hip replacement. However, the 
patients receiving autologous blood were mainly operated by one surgeon and the patients 
transfused with allogeneic blood were operated by another surgeon. It is known from the 
study by McArdle and Holel6 that infectious complications are surgeon related and 
therefore we believe that their conclusion that autologous transfusion decreased the rate of 
infectious complications is questionable. Fernandez et al. 17 also reported on orthopedic 
operations and infectious complications in relation to transfusions and failed to find any 
beneficial effect of autologous blood as compared to allogeneic blood. It was found that 
the only transfusion related factor affecting the incidence of infections was transfusion of 
whole blood. 
The patients in these studies had to undergo procedures for which the operation could be 
postponed for a long time. For example, collection of autologous blood in orthopedic 
patients can take several months. Therefore additional allogeneic transfusions are less 
often needed than in colorectal cancer patients in which long postponement of the 
operation is not acceptable. Another difference is the rate of infectious complications. In 
orthopedic procedures infections were found in less than 10% of the cases whereas in 
colorectal surgery infectious complications occur in about 25% of the patients. The 
incidence of infections in our study are comparable to the other studies investigating the 
relationship between blood transfusions and infections after abdominal surgery. IS 
In contrast to the aforementioned studies our trial had a multicenter design which could 
have influenced the outcome. To investigate a possible diluting effect due to interhospital 
variance we calculated the odds-ratios for infections per hospital separately. None of the 
separate odds-ratios reached significance, neither did the odds-ratios differ significantly 
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from each other. Therefore there was no negative effect of multicentricity, whereas the 
advantage of such a design was the recruitment of a large amount of patients, which is 
necessary for proper conclusions on infectious complications. 
It has been postulated that the inununologic changes induced by blood transfusions are a 
result of the transfusion of white cells. 19 Jensen et al.20 reported a decreased incidence 
of wound infections after leukocyte depletion as compared to patients transfused with 
whole blood. However, no differences were found for the overall rate of infectious 
complications. A larger study by Houbiers et a!." compared filtered blood with buffy-
coat depleted packed red cells, which is the same blood product as we used in our study. 
They found no significant difference between the study arms for the overall rate of 
infections nor the rate of wound infections. However, it was found that transfused patients 
had a significantly higher rate of infections than the patients who did not undergo 
transfusion. In regression analysis Houbiers ct at found, that the only influencing factors 
were transfusion of red cells and tumor location. In agreement with this our study showed 
that blood transfusion, the tumor location and the age of the patients did affect the risk of 
infections significantly. Because randomization was not a risk factor of infections we 
conclude that a predeposit autologous blood donation program does not reduce the 
incidence of infectious complications after colorectal cancer surgery.22 There is no 
advantage of transfusing autologous blood for reducing postoperative bacterial infections. 
An important risk factor for infection is transfusion of more than two units of blood. An 
explanation for this finding could be that the immunologic changes induced by allogeneic 
transfusions are also generated by the transfusion of autologous blood. So far no such 
immunomodulatory effects of autologolls blood have been demonstrated.23.24.25 
Therefore, the most likely explanation for our findings is that not the blood transfusions 
themselves but rather the circumstances necessitating them are the real factors influencing 
the risk of infectious complications. This is consistent with our earlier conclusion about 
the association between blood transfusions and colorectal cancer prognosis.26 Of course 
blood transfusion is highly related to blood loss and surgical extent. It is known from 
animal and clinical studies that surgical trauma and blood loss induce 
imrnunosuppression.12.27.28 It is therefore advisable to restrict these two factors to a 
minimum, thereby minimizing the need for transfusions. ill colorectal cancer surgery this 
will be of benefit for the oncologic prognosis and the rate of infectious complications. 
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Summary 
Transfusion-induced immunosuppression has long been known to be beneficial for organ 
transplantation patients, but recent retrospective studies suggest that blood transfusions 
may be detrimental for patients with cancer. If autologous blood is used to avoid 
immunosuppressionJ the assumption is that the procedure, involving blood donatioo, is 
immunologically neutral. In the present study, this assumption was evaluated by 
monitoring 33 normal blood donors and 16 colorectal cancer patients before and after 
donation of I (500 mI) and 2 units of blood, respectively. The cancer patients belonged to 
the autologous arm of a randomized trial in which the effects of allogeneic versus 
autologous blood on cancer proguosis were studied. The patients donated 2 units of blood 
with an interval of 3 to 4 days between donations. Flow cytometric analysis revealed that 
blood donation by normal donors and cancer patients had no effect on the proportion of B, 
T, and natural killer (NK) cells. Only the total number of lymphocytes was significantly 
decreased in the normal donors on Day 12 after donation. Blood donation had no 
significant effect on T cell function assessed by phytohemagglutinin stimulation in normal 
donors or in cancer patients donating 2 units of blood. A significant depression of NK cell 
function (88% and 74% of predonation levels) was observed in normal donors on Days 2 
and 5 after donation; on Day 12, the activity was again normal. Colorectal cancer patients 
had a significantly depressed NK cell activity (54% of predonation activity) on Day 12 
after the first donation. Before donation, the NK cell activities of blood donors and cancer 
patients were similar (45.6 ± 4.3% and 41.4 ± 3.6%, respectively, at the 50:1 ratio). 
Before donation, the number of NK cells correlated significantly with NK cell activity, 
but, after donation, such a correlation was lacking. This study indicates that blood 
donation, especially the donation of 2 units, leads to a depressed NK cell activity. If 
confirmed in a larger study I this finding may have important implications for cancer 
patients undergoing surgery. 
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Introduction 
Autologous blood is becoming increasingly popular as an alternative for allogeneic blood. 
This change in blood transfusion policy is based on the awareness that allogeneic 
transfusions involve the risk of infection and induction of immunosuppression,l,2 
Transfusion-induced immunosuppression has long been known to be beneficial for organ 
transplantation patients, but recent investigations suggest that it may be harmful for 
patients with cancer.3.4 Various retrospective studies have identified allogeneic blood 
transfusion as an independent risk factor for recurrence in and survival of cancer patients. S 
However, in other studies,6,7 such a correlation could not be demonstrated. Although this 
putative negative effect of blood transfusion has not yet been confirmed by prospectively 
randomized clinical studies, it has stimulated considerably the use of preoperatively 
deposited autologous blood. When autologous blood is used to avoid immunosuppression, 
an important assumption is that the donation and transfusion of this blood are 
immunologically neutral. This assumption may be wrong, since it is known from animal 
studies that hemorrhage can lead to a marked and long-lasting depression of both specific 
and nonspecific immunity.' It has also been demonstrated that long-term blood donation 
can lead to a depression in natural killer (NK) cell activity in the blood donors, without, 
however, leading to any adverse clinical manifestation.9 Although these studies relate to 
rather extreme situations that do not occur during the preoperative deposit of autologous 
blood, they stiii are intriguing and warrant further investigation of the immunologic effects 
of simple blood donation. The question addressed in the current study therefore was 
whether the donation of I or 2 units of blood might lead to some form of 
immunosuppression. The investigations were performed in the period immediately 
following blood donation and employed normal blood donors and colorectal cancer 
patients participating in a preoperatively deposited autologous blood transfusion 
program. 1O 
Materials and methods 
Nomral donors and callcer patients 
Thirty-three blood donors and 16 colorectal cancer patients were included in the study. 
The normal blood donors were recruited from volunteer donors at the Red Cross Blood 
Bank in Rotterdam, The Netherlands. They were ali more than 40 years old and had been 
donating blood for more than two years, at a frequency of twice per year. After they gave 
informed consent, 40 ml of blood for immunologic testing was taken before and after the 
donation of I unit (500 mil of blood. The first group of 18 donors (II men, 7 women) 
was tested immediately before donation and 2 and 5 days after donation. Because we 
found that the NK ceil activity in this group was still abnormal on Day 5, we tested a 
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second group of 15 blood donors (5 men, 8 women) to see whether NK cell activity would 
still be low 12 days after donation. The NK cell activity in this group was measured 
before donation and on Days 5 and 12. 
The 16 colorectal cancer patients were participants in a multicenter trial on the effect of 
blood transfusions on cancer recurrence and survival. lO In this trial, patients were randomly 
assigned to receive preoperatively deposited autologous blood or allogeneic blood (buffy-
coat depleted). The patients included in the current immunologic study were randomly 
assigned to the autologous arm of the trial, and all were scheduled for potentially curative 
surgery at the University Hospital Dijkzigt (Rotterdam). There were seven men and nine 
women, ranging in age from 31 to 84 years. We did not include patients with a history of 
blood transfusion or those who had earlier cancer, familial polyposis, or ulcerative colitis. 
The patients fulfilled the criteria set for autologous blood donation by the American 
Association of Blood Banks." The study was approved by the ethics committee of the 
hospital. The patients donated a total of 2 units of blood with an interval of 3 to 4 days 
between the two donations. Blood for immunologic monitoring was taken 2 days before 
the first donation and 8 to 9 days after the second donation (Day 12). 
Flow cytollletry 
We analyzed subsets of lymphoid cells with a fluorescence-activated cell scanner 
(FACScan, Becton Dickinson, Mountain View, CA, USA) and used software (SimuISET, 
Becton Dickinson) for lymphocyte gating and determination of proportions of lymphocyte 
subsets. We mixed 100 ~I of heparinized blood in separate tubes with 20 ~I of the 
monoclonal antibodies listed in Table 6.1 for 30 minutes at room temperature. All 
monoclonal antibodies were purchased from Becton Dickinson. Red cells were lysed 
(FACS lysing solution, Becton Dickinson), and the remaining lymphoid cells were washed 
three times with phosphate-buffered saline. The first sample from a given subject was used 
to identify the proportions of lymphocytes, monocytes, and granulocytes. This was done 
by a combination of antigen expression (CDI4 on monocytes, granulocytes, and 
macrophages) and light-scattering characteristics. Gates were set to exclude the 
lymphocytes, and this gate setting was used for all subsequent samples from that person. 
In the second sample, we used antibodies against keyhole-limpet hemocyanin (KLH) as 
control for aspecific binding. We calculated absolute numbers of the different subsets by 
multiplying the proportion of positive cells by the total number of lymphocytes. 
Phytohemagglutinin stimulation assay 
Peripheral blood mononuclear cells were isolated by gradient centrifugation using 
lymphocyte separation medium (Litton Bionetics, Chatsworth, CAl. They were washed 
three times and resuspended in medium (RPMI-1640, Gibco Laboratories, Grand Island, 
NY) containing 10% fetal calf serum and 10' molll Il-mercaptoethanol. Using round-
bottom mlcrotiter plates (Nunc, Roskilde, Denmark), we added 20 ~l of phyto-
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hemagglutinin (PHA; Wellcome, Dartford, UK) in different concentrations (6.25, 12.5,25, 
50, and 75 Jlglml) to triplicate cultures of 20 Jll of lymphocyte suspension containing 7.5 x 
10' cells per ml. Six hours before termination, each culture was labeled with 0.8 JlCi of 
methyl-3-H-thymldine (specific activity, 2 Cilmrnol; Amersham, UK). The cultures were 
harvested with an automatic microtiter plate harvester (Automash, Dynatech, Baton Rouge, 
LA). We collected cells on fiberglass filters; after drying them, we placed the filters in 
vials, added scintillation fluid, and determined the uptake of methyl-3-H-thymldine in a 
liquid scintillation counter. 
Table 6,1, Monoclonal antibodies used in flow cytometry. 
Sample Antigen Antibody Cellular distribution 
CDI4 Anti-leuM3-PE Monocytes 
Granulocytes 
Macrophages 
2 KLH Ig-G2-PE Control-aspecific 
2 KLH Ig-GI-FlTC binding 
3 CDI9 Anti-Jeu 12-PE B cells 
3 cm Anti-leu4-FITC T cells 
4 CD4 Anti-leu3a-PE T4 cells 
4 CDS Anti-leu2a-FITC T8 cells 
5 CDI6 Anti-ieuti-PE NK cells 
Granulocytes 
Macrophages 
5 CDS Anli-leu2a-FITC T8 cells 
6 CDI6 Anti-Ieutl-PE NK cells 
6 CD57 Anti-leu7-FITC Granulocytes 
Macrophages 
NK cells 
7 CD3 Anti-leu4-PE T cells 
7 'CD57 Anli-leu7-FlTC NK cells 
PE: Phycoerythrin, red fluorescence 
FITC: Fluorocein isothiocyanate, green fluorescence 
KLH: Keyhole limpet hemocyanin 
T4: T helper/inducer cells 
T8: T cytotoxic/suppressor cells 
Natural killer (NK) cell assay 
For the NK cell assay, we used the human erythroleukemlc cells, K562, which are the 
prototype of NK-sensitive targets. NK cell activity was measured in a 4-hour assay using 
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gradient-separated lymphocytes and "Cr-Iabeled K562 target cells. We performed the 
assay in triplicate in round-bottom microtiter plates (Nunc) by adding lymphocytes to I x 
104 target cells at ratios of 6.25:1, 12.5:1,25:1, and 50:1. The plates were centrifuged for 
3 minutes at 150 x g and then incubated for 4 hours at 37"C in a humidified 5% CO, 
incubator. To harvest the culture, we centrifuged plates for 3 minutes at 150 x g and 
removed the supernatants using a collection system (Skatron, Lier, Norway)." The 
release of label was determined by counting radioactivity in a gamma counter (counts per 
minute = cpm). We assessed spontaneous release (SR) in target cell cultures without 
lymphocytes and determined the maximal release (MR) by adding 10% cetavlon detergent. 
The percentage of specific lysis was calculated according to the following formula: 
mean cpm experimental - mean cpm SR 
x 100% 
mean cpm MR - mean cpm SR 
NK cell activities are presented for the 50: I Iymphocyte-to-target cell ratio. 
Statistical analysis 
The significance of differences was evaluated by using the Mann-Whitney test and the 
paired Wilcoxon test. A p value <0.05 was considered statistically significant. 
Results 
Effect of blood dOllatioll Oil lymphocyte sllbsets 
We performed subset analysis in the second group of IS normal blood donors and in the 
group of colorectal cancer patients. The normal volunteers donated I unit of blood, and 
samples for monitoring were taken before donation and on Days 5 and 12 after donation. 
The cancer patients donated 2 units of blood with an interval of 3 to 4 days between 
donations; monitoring was done before the first donation and 12 days after. In the normal 
blood donors, the number of white cells remained stable after donation. The mean 
percentage of lymphocytes dropped from 32.6% before donation and 33.3% on Day 5 to 
25.4% on Day 12 (p=0.02) (Table 6.2). As a consequence, the absolute number of 
circulating lymphocytes on Day 12 was less than before donation (p=O.OI). The 
proportions of B, T, and NK cells did not change, nor did the CD4:CD8 ratio, but the 
absolute numbers were significantly lower than before donation (Figure 6.1). In the 
colorectal cancer patients the number of white cells and the percentage of lymphocytes did 
not change after blood donation. Nor did the proportion and number of B, T, and NK cells 
change significantly (Table 6.2 and Figure 6.1). 
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Figure 6.1. Effect of blood donation by normal donors and colorectal cancer patients 
on number (x 10'/1) of lymphocytic subpopulations (see Table 6.1). 
The upper part gives the results of normal blood donors before and after donation of I 
unit of blood; the lower part represents the results obtained in colorectal cancer patients 
before and after donation of 2 units of blood. (. denotes p value <0.05). 
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Table 6.2. Effect of blood donation on the proportion of lymphocytes and 
lymphocyte subsets. 
Lymphocytes B cells T cells NK cells 
Blood donors 
Day 0 32.6% 11.3 % 74.6 % 12.9 % 
Day 5 33.3 0/0 10.6% 75.1 % 13.5 % 
Day 12 25.4 %' 10.2 % 76.1 % 12.5 % 
Colorectal cancer patients 
Day -2 23.2 % 15.8 % 65.2 % 18.7 % 
Day 12 19.8 % 12.2 % 69.5 % 17.8 % 
Significantly (p=O.02) different as compared with Day 0 level. 
Effect oj blood dOllatioll all T lymphocyte jllllctioll 
Donation of 1 unit of blood by the first group of 18 voluntary blood donors did not result 
in a significant change in PHA response immediately after donation or on Days 2 and 5. 
Donation of 2 units of blood by colorectal cancer patients led to a mean decrease of 30% 
in PHA response on Day 12; however, this decrease did not reach significance (Table 6.3). 
Table 6.3. Effect of blood donation on PHA response.' 
Blood donors 
Day 0 
Day 2 
Day 5 
Colorectal cancer patients 
Day -2 
Day 12 
PHA response 
(mean ± SEM) 
122.8 ± 9.5 
126.4 ± 9.3 
116.8 ± 7.3 
70.1 ± 11.9 
49.0 ± 13.1 
The results are given in CQunts x 103 per minute. 
Effect oj blood dOllatioll all NK cell activity 
Range 
19 - 190 
42 - 186 
73 - 177 
25 - 130 
9 - 112 
In the first group of blood donors, the NK cell activity, relative to predonation activity, 
was 104% immediately after donation, 88% on Day 2 (p=0.02), and 68% on Day 5 
(p<0.02). We observed a sintilar depression (74% of predonation activity) on Day 5 in the 
second group of donors, whereas on Day 12, the NK cell activity was again normal 
(117%) (Figure 6.2). 
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Effect of blood donation OIl NK cell activity (± SD) ill healthy blood 
donors donating 1 unit of blood and in colorectal cancer patients donating 
2 units of blood. 
NK cell activity is given as percentage of predonation value. ( • denotes p value <0.05). 
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Colorectal cancer patients were tested before and 12 days after the first donation, or 9 
days after the second donation. On Day 12. the NK cell activity was only 54% of 
predonation activity (p=0.OO2) (Figure 6.2). There was no difference in predonation NK 
cell activity in blood donors and cancer patients. The specific release at the 50: I 
Iymphocyte-to-target cell ratio was 41.4 ± 3.6% (mean ± SEM) in colorectal cancer 
patients and 45.6 ± 4.3% in blood donors. Before donation, there was a significant 
correlation between NK cell activity and the proportion of NK cells analyzed by flow 
cytometry (p=0.016). The correlation was 0.61 with regard to Leu-ll'?' cells and 0.71 for 
Leu-ll'7' cells. There was no significant correlation between NK cell activity and the 
proportion of Leu-In' cells. These cells appeared to be positive for CD3 markers and 
thus probably were T cells. The decreased NK cell activity observed in normal blood 
donors on Day 5 and in colorectal cancer patients on Day 12 no longer correlated 
significantly with the total proportion of NK cells. The correlation was 0.44 on Day 5 and 
0.35 on Day 12. 
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Discussion 
The present observations demonstrate a significant decrease in NK cell activity in 
voluntary blood donors and cancer patients after the donation of I or 2 units of blood, 
respectively. Donation of I unit of blood resulted in a decreased NK cell activity lasting 
for at least 5 days. In cancer patients who donated 2 units of blood, this decrease was still 
demonstrable after 12 days, which suggests that the duration of NK cell depreSSion may be 
related to the amount of blood taken. Alternatively, it is conceivable that blood donation 
has a more profound impact on NK cell function in cancer patients than in healthy blood 
donors. Decreased NK cell activity in relation to blood donation was observed earlier by 
Lasek et a!.' However, those investigators focused not on the phase immediately following 
blood donation but on the long-term effect of frequent donation. Patients were monitored 
at least 3 months after the last donation. It was found that the NK cell activity in frequent 
blood donors was significantly decreased as compared to that in age-matched controls. The 
magnitUde of the decrease appeared to be related to the total amount of blood donated, 
with the lowest values seen in active long-term donors. In seeming contrast to these 
findings are the observations by Lewis et al.,13 who found that long-term blood donation 
had no effect on the percentage of NK cells in peripheral blood. However, NK cell 
activity was not measured, though this may be more important than monitoring of NK cell 
numbers. Our findings indicate that there indeed may exist a discrepancy between the 
proportion of NK cells and NK cell activity. Although the proportion of NK cells 
remained unaffected after blood donation, we still observed that the NK cell activity 
dropped significantly. Prolonged impairment of NK cell activity following simple 
hemorrhage without tissue trauma has been demonstrated in mice by Stephan et a!." 
These investigators drew blood from mice until they reached a mean blood pressure of 35 
mrnHg, which was maintained for I hour, after which the animals were resuscitated. Up to 
6 days after hemorrhage, the NK cell activity of spleen cells was profoundly depressed. 
The same group of investigators demonstrated that also T cell related functions like PHA 
response, mixed lymphocyte reaction, and interleukin-2 production also were severely 
depressed following hemorrhage.,,·16 In our study, we did not observe a significant 
change in T cell function at any time after blood donation. The only alteration observed 
was that, at 12 days after the donation of I unit of blood, the absolute number of T cells 
was decreased. 
The depression of NK cell activity by blood donation is the major finding of our study 
may be caused by several mechanisms, as proposed earlier by others.9 First. it is known 
that hemorrhage is a potent stimulator of corticosteroid and prostaglandin secretion. These 
mediators have been demonstrated to inhibit NK cell activity, and they may have been 
responsible for the decline in NK cell activity after blood donation. Second, it is possible 
that blood donation leads to a shifting of mature NK cells from the blood to the bone 
marrow and lymphoid organs, which leads to the recruitment in the blood of immature NK 
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cells with lower activity. This explanation is not likely to hold for our present findings, 
since it was found that, after donation, the absolute number and proportion of NK cells 
remained unchanged, whereas their activity decreased. 
The important question remains whether the results emerging from our study bear any 
clinical relevance. NK cells are believed to playa role in the first-line defense against 
tumor growth and infection.17·!' Therefore, a reduced NK cell activity may be 
detrimental for normal patients and even more so for patients with cancer. Evidence that 
NK cells are involved in tumor development and metastasis is mainly derived from tumor 
transplantation studies in rodents. Among the many studies performed on this subject, a 
cmcial observation was that experimental tumor metastasis was enhanced in strains of 
mice with low NK cell activity but reduced in strains exhibiting high NK cell 
activity.19,20 Furthermore, the selective elimination of NK cells by monoclonal 
antibodies has been reported to decrease the survival of animals injected with tumor 
cells.'! In the clinical situation, the role of NK cells in growth and destruction of tumors 
is less clear. A correlation between low NK cell activity and tumor progression has been 
reported by many authors," and, conversely, high NK cell activity at the site of the 
tumor has been found to correlate with tumor regression.23 The strongest support for the 
notion that NK cells may be of significance in cancer is provided by studies in which the 
adoptive transfer of interleukin-2 activated NK cells was found to have some therapeutic 
effect." 
The role of NK cells with regard to susceptibility for infection seems less speculative. In 
murine models, it has been found that the depletion of NK cells resulted in a marked 
increase in death as a result of otherwise sublethal challenges with virus?5 More 
important, a recent study performed in healthy volunteers demonstrated that subjects 
exhibiting a persistently low level of NK cell activity were more at risk for developing 
infectious disease than individuals with normal NK cell activity." In addition, Siegal et 
al.27 showed that opportunistic infections in acquired immune deficiency syndrome 
patients developed only if both T cell and NK cell activity were depressed. 
It seems reasonable to assume that the short-term depression of about 30% of NK cell 
activity observed in our group of normal blood donors fell within the range of normal 
physiologic fluctuation of NK cell activity and has no clinical significance. It has been 
demonstrated earlier that the intra-individual day·to-day variation in NK cell activity using 
K562 targets is about 13%, and that the variance between subjects is 20%." The 
importance of the depression in NK cell activity may be quite different for the cancer 
patients participating in the autologous blood transfusion trial. These patients had donated 
2 units of blood and were still low in NK cell activity 12 days after the first donation. 
They were scheduled for major surgery on Day 14 and presumably were still low in NK 
cell activity at the time of operation. It is conceivable that, through this depression in NK 
cell activity, in conjunction with the immunosuppression evoked by surgery, these patients 
are more susceptible for the development of metastases and infection. We showed earlier 
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in an artificial metastasis model in rats29 that the donation of blood, alone or in 
combination with surgery, leads to enhanced tumor growth. In addition, blood donation in 
this rat model led to a significant decrease of NK cell activity." It has frequently been 
demonstrated that, during surgery for cancer, many tumor cells are released into the 
circulation; the homing of these cells may be facilitated by the low level of NK cell 
activity at this crucial moment.'! Relevant in this respect is the finding by Tartter et 
al." that colorectal cancer patients with low preoperative levels of NK cell activity were 
at increased risk for tumor recurrence. In addition, an impaired NK cell function has 
recently been linked to the occurrence of wound infections in patients undergoing elective 
colorectal surgery. 33 
It is obvious that our preliminary results on the effects of postdonation NK cell activity 
require confirmation in larger groups of patients before definite conclusions can be drawn 
or measures for intervention can be advocated. 
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Summary 
Autologous blood transfusions are used to overcome the immunological consequences 
induced by allogeneic blood. However, predeposit autologous blood transfusion requires 
blood donation, which has been demonstrated by us to decrease natural killer cell activity 
in colorectal cancer patients. This study investigates the effects of blood donation on 
prognosis and infectious complications after colorectal cancer surgery. We analyzed a 
subgroup of patients (N=135) who had not required transfusions in a randomized trial 
comparing the effects of autologous versus allogeneic blood transfusions in colorectal 
cancer surgery. Patients in the autologous group had donated two units of blood 
preoperatively. 
In the control group 22% (20/92) and in the donation group 16% (7/43) had infectious 
complications (p=0.61). Differences regarding the risk of infections were also not 
demonstrated using multivariate analysis. 
The colorectal cancer-specific survival at 4 years of all patients was 83% in the control 
group and 72% in the donation group (p=0.30). The disease-free survival at 4 years of 121 
patients who underwent curative surgery was 74% in the control group and 78% in the 
donation group (p=0.94). Multivariate analysis also did no reveal significant differences in 
prognosis between the groups. 
We conclude that the donation of two units of blood for autologous transfusion in 
colorectal cancer patients did neither affect the incidence of infectious compllcations. nor 
affect the prognosis of those patients. 
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Introduction 
In the last decades autologous blood transfusions have become more popular because 
doctors and patients fear the risks of allogeneic transfusions. Especially the risk of 
transmission of viral infections, but also the induction of immunosuppression by allogeneic 
blood transfusions may be harmful for operated patients. Although recently prospective 
studies have given more insight whether transfusion-induced immunosuppression has a 
negative effect on cancer prognosis, this topic is still not fully explained.' However, it is 
known that preoperative autologous blood donation is a safe procedure and therefore it is 
one of the best alternatives for third party (allogeneic) blood transfusions. 
In a multicenter randomized clinical study in colorectal cancer patients, we investigated 
the effects of autologous blood transfusions as compared to standard allogeneic 
transfusions. We came to the conclusion that a detrimental effect of allogeneic transfusions 
on cancer prognosis, whenever it exists, can not be overcome by the use of a predeposit 
autologous blood transfusion program. Obviously, the use of autologous blood transfusions 
requires the donation of blood. Blood donation in healthy donors can reveal changes in 
immunologic parameters and we have found also that blood donation leads to a significant 
decrease in natural killer cell activity in colorectal cancer patients.'" The present study 
was performed to investigate whether blood donation prior to surgery for colorectal cancer 
had any effect on prognosis and on the incidence of postoperative infectious 
complications. For this purpose we analyzed a subgroup of patients who participated in the 
above mentioned randomized study. To eliminate the putative effects of blood transfusions 
we excluded the patients who received any type of transfusion from the present analyses. 
Materials and methods 
The evaluated patients participated in a randomized multicenter trial to investigate the 
effect of autologous blood transfusions on prognosis of colorectal cancer as compared to 
standard allogeneic transfusions. The design of this trial has been described In detail 
elsewhere.' This multicenter study was performed in 15 hospitals and was approved by 
the ethics committees of all the participating centers. After written informed consent had 
been obtained, eligible patients were randomiy assigned to either the allogeneic group or 
the autologous group. The enrollment of the patients took place from August 1986 to 
November 1991. All patients who were scheduled for a curative resection of colorectal 
malignancy were eligible for the study, if they fulfilled the criteria set for autologous 
blood donation by the American Association of Blood Banks.' These criteria required the 
absence of severe cardiovascular or respiratory disease, no history of epilepsy after 
infancy, and a hemoglobin concentration above 11.3 gldl (7 nUTIol/l). In addition, the 
patients had no history of blood transfusion during the last three months before 
randomization. 
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The patients who were assigned to the autologous group were required to donate blood 
twice. The minimum interval between the two donations was 72 hours, and the second 
donation had to occur not later than five days before surgery. At each donation, 450 mI of 
blood was obtained by standard procedures. The patients were treated with oral iron 
supplementation, ferrous fumarate 3 times daily 200 mg, immediately after randomization. 
The collected blood was separated into packed red blood cells (without buffy coat) and 
freshwfrozen plasma, except at one hospital, where autologous blood was given in 
transfusion as whole blood. Packed cells were given if blood loss exceeded 500 mI or the 
hemoglobin level dropped below 10.5 gldl. Fresh-frozen plasma was transfused when 
indicated. 
Antibiotic prophylaxis and bowel irrigation were given routinely. After standard surgical 
procedures the tumors were staged according to the Turnbull' modification of the Dukes' 
classification. The patients underwent a standard follow-up program, and when indicated 
histologic or cytologic evidence of recurrent disease was obtained. 
In the present study, which was performed to explore the effect of blood donation in 
patients who were operated for colorectal cancer, all transfused patients and the patients in 
the autologous group who did not donate blood were left out of the analyses. 
Consequently, 135 of the 475 randomized patients remained for the present analysis. Of 
these patients the one in the autologous group were exposed to blood donation and called 
the donation group, whereas the patients in the allogeneic group were called the control 
group. 
Colorectal cancer-specific survival and disease-free survival curves were calculated 
according to the Kaplan-Meier method,' and the log rank test was used to compare these 
curves. Multivariate analyses of survival data were performed by Cox regression.8 
Percentages were compared by the chi-square test. Logistic regression' was used to 
investigate various factors simultaneously regarding the incidence of infectious 
complications. Two-sided p values ';;0.05 were considered statistically significant. 
Results 
Of the 475 patients who participated in the above mentioned randomized multicenter trial, 
135 patients remain for this study. Of these, 92 patients were in the control group and 43 
patients in the donation group. All the 43 patients in the donation group donated two units 
of blood prior to surgery. The characteristics of the patients were not significantly 
different between the two groups (Table 7.1). The discrepancy between both groups 
regarding the number of patients can be explained by the fact that patients in the 
autologous group more often required blood transfusions as a result of the hemoglobin 
decrease by blood donation. 
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Table 7.1. Characteristics of the untransfused patients per group. 
Conlrol group Donation group 
(N = 92) (N = 43) 
Age 
:::; 60 years 26 (28%) 16 (37%) 
> 60 & :::; 70 years 35 (38%) 16 (37%) 
> 70 years 31 (34%) II (27%) 
Sex 
Male 51 (55%) 26 (61%) 
Female 41 (45%) 17 (40%) 
Tumor location 
Inlra-abdominal 56 (61%) 28 (65%) 
Rectal involvement 36 (39%) 15 (35%) 
Dukes' classification 
A 25 (27%) II (26%) 
B 32 (35%) 10 (23%) 
C 28 (30%) 15 (35%) 
D 7 (8%) 7 (16%) 
Histological differentiation 
Well 13 (14%) 7 (16%) 
Moderate 69 (75%) 30 (70%) 
Poor 10 (11%) 6 (14%) 
Adjacent organ fixation 
No 86 (94%) 41 (95%) 
Yes 6 (6%) 2 (5%) 
Table 7.2. Logistic regression of various factors regarding the risk of infectious 
complications of untransfused patients (N=135). 
Factor No. of patients Odds ratio 95% p value 
infected/total (%) confidence 
interval 
Tumor location 
Intra-abdominal 14/84 (17%) I 
Rectal involvement 13/51 (26%) 1.9 0.8·4.7 0.16 
Age 
:::; 60 years 3/42 (7%) I 
> 60 & :s; 70 years 11151 (22%) 4.0 1.0 . 16.0 0.046 
> 70 years 13/42 (31%) 5.9 1.5·23.1 0.01 
Study group 
Control group 20/92 (22%) I 
Donation group 7/43 (16%) 0.8 0.3·2.1 0.65 
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In the control group 20 patients (22%) had postoperative infectious complications as 
compared with 7 patients (16%) in the donation group (p=0.61). In logistic regression 
analysis, including also tumor location and age of the patient, the factor study group was 
not an influencing factor for the risk of infectious complications (Table 7.2). Only the age 
of the patient was a significant risk factor of infections. 
During the study, 12 patients in the control group and 9 patients in the donation group 
died of colorectal cancer, whereas no patient died of another cause. Figure 7.1 shows that 
the colorectal cancer-specific survival did not significantly differ between the studied 
groups; the colorectal cancer-specific survival at 4 years was 83% in the control group and 
72% in the donation group (p=0.30). Of the 121 patients, who underwent curative surgery, 
15 of the 85 patients in the control group and 6 of the 36 patients in the donation group 
had recurrent disease during follOW-Up. 
Figure 7.1. Colorectal cancer-specific survival in all 135 patients after colorectal cancer 
surgery without transfusions. 
The survival at 4 years was 83% ill the control group and 72% in the donation group 
(p=0.30). 
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Table 7.3. Multivariate analysis of various factors with respect to recurrence rate of the 
patients who underwent curative surgery without transfusions (N=121). 
Factor Relative 95% p value 
recurrence rate confidence 
interval 
Study group 
Control group t 
Donation group 0.9 0.3 - 2.6 O.SI 
Age 1.0 0.9 - 1.0 O.IS 
Sex 
Male I 
Female 0.7 0.3 - 1.9 0.52 
Dukes' classification 
A I 
B 3.0 0.3 - 26.S 0.33 
C 14.5 I.S - llS.6 0.01 
Tumor size l.l 0.9 - 1.3 0.32 
Differentiation 
Well I 
Moderate l.l 0.2 - 5.9 0.94 
Poor 1.9 0.2 - 14.7 0.56 
Operation 
Intra·abdominal t 
Rectal involvement l.l 0.4 - 3.1 0.7S 
Adjacent organ fixation 
No I 
Yes 0.3 0.Q3 - 2.4 0.25 
• As compared to 1 year younger (age), or 1 em smaller (tumor size). 
Figure 7.2 indicates that the disease-free survival of the 121 patients. who underwent 
curative surgery. were not significantly different between both groups; the disease-free 
survival at 4 years was 74% in the control group and 78% in the donation group (p=O.94). 
Table 7.3 shows the results of Cox regression of various factors with respect to the 
recurrence rate of the patients who underwent curative surgery (N=121). Study group was 
not a factor affecting the recurrence rate (p=O.81). The only significant factor 
influencing colorectal cancer prognosis in these patients was the Dukes' classification. 
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Figure 7.2. Disease-free survival of 121 patients who underwent curative surgery for 
colorectal cancer without transfusions. 
The disease-free survival at 4 years was 74% in the control group and 78% in the 
donation group (p=0.94). 
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DiscussIon 
This study shows that donation of two units of blood preoperatively. did not alter the 
recurrence rate and the survival of colorectal cancer patients. So far, no data are available 
of the effects of blood donation in cancer patients. The only published reports investigated 
the incidence of cancer among healthy blood donors. Merk et al.1O found in a study of 
37.795 Swedish blood donors that the incidence of cancer was significantly less as 
compared to the expected value. The relative risk was 0.79 for donors (p<O.OOI). As an 
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explanation for these findings, which were in sharp contrast with their primarily 
hypothesis, the authors postulated that the results might be influenced by selection of the 
blood donors. Lasek et al. lI found a long lasting depression of the natural killer cell 
activity after long-term blood donations, and recently came to the conclusion that these 
immunological changes did not bear any clinical consequence with respect to the incidence 
of cancer. In a study among 3126 voluntary blood donors in Poland no significant 
difference in the observed and expected number of cancer cases (all types) was found. 
They observed an increased risk of developing liver cancer, but it seems unlikely that this 
is a reflection of depressed natural killer cell activity among those patients. Tartter et 
al. 12 have found that a low natural killer cell activity is related to an increased risk of 
colorectal cancer recurrence. Although the exact role of natural killer cells is unclear, this 
might be a result of their immune-surveillance against circulating cancer cells. 13.14 
Because blood donation decreases natural killer cell activity significantly, it was 
questionable whether this procedure is as safe in colorectal cancer patients as it is in 
healthy blood donors. The results of this study clearly shows that the impaired function of 
natural killer cells induced by blood donation had no clinical impact on the prognosis of 
colorectal cancer patients. 
With respect to the risk of infectious complications after colorectal cancer surgery, we did 
also not observe any effect of blood donation. In a earlier study we found that the risk of 
infections was affected by the location of the tumor and an increased age. I' Autologous 
blood transfusions did not decrease the rate of infectious complications as compared to 
allogeneic transfusions. Heiss et al. 16 suggested in a similar but smaller study that 
patients in the autologous group had less infections. Whether this marginally significant 
difference was a result of the different effects of allogeneic and autologous blood 
transfusions was unclear. Another explanation stated by the authors was that the donation 
of blood could have a protective effect against bacterial infections in the postoperative 
period. We performed multivariate analysis allowing for various potential risk factors, 
including also whether blood was donated or not. Using this method there was no 
significant difference between these two groups, which made us conclude that preoperative 
donation of blood in colorectal cancer surgery does not affect the risk of infectious 
complications. 
Jensen et al.17 found that an impaired natural killer cell activity is related to an increased 
rate of wound infections after colorectal surgery. They have found a decreased natural 
killer cell activity induced by transfusions of whole blood as compared to leukocyte-
depleted blood. Although the overall rate of infections was similar in both groups, the 
patients transfused with Whole blood had more wound infections as compared to the 
patients transfused with filtered blood. In a larger study by Houbiers et al. 18 comparing 
leukocyte-depleted blood with buffy-coat depleted blood no differences in infectious 
complications were found. We did not find that a decreased natural killer cell function, 
due to blood donation, had any impact on the rate of infections, but this might be 
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otherwise when the immunological changes are induced by transfusions. The effects of 
transfusions or donation on natural killer cell function and other immunological parameters 
might be totally different. In the present study we have not analyzed the effects of 
transfusions on natural killer cell function because all transfused patients were excluded, 
but the impairment of natural killer cell function induced by blood donation did not affect 
the risk of infectious complications after colorectal cancer surgery. 
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CHAPTERS 
GENERAL DISCUSSION 
Chapter 8 
Introduction 
Blood transfusions have an immunosuppressive effect. which is beneficial for patients 
receiving a kidney transplantation. It is suggested that this transfusion-induced 
immunosuppression may have detrimental effects in patients operated for cancer. I Due to 
allogeneic blood transfusions in the perioperative period the prognosis of cancer patients 
might be impaired, and the rate of postoperative infectious complications might be 
increased. Several retrospective studies indeed found that these deleterious effects occur in 
colorectal cancer patients. Experimental studies showed that growth of certain tumors was 
enhanced after allogeneic blood transfusions, which suggests that the relationship between 
blood transfusions and impaired cancer survival might be causal. However, there are also 
conflicting data from both experimental and clinical studies. Transfusions are given either 
because of the disease or as a result of surgical treatment. Therefore it is questionable, 
whenever a relationship between transfusions and cancer prognosis would exist, whether 
this relationship is causal or indirect. The need for transfusion could be an indicator of 
other prognostic factors, which are unknown, and therefore blood transfusion is 
coincidentally related to prognosis. The only way to resolve the question of causality is to 
perform a randomized trial comparing transfused patients with patients who did receive 
transfusions. Unfortunately, it is disputable whether such a trial design is ethically 
justified. Although the causality of the putative relationship can not be resolved 
completely it is possible to investigate whether the effects of allogeneic blood transfusions 
can be overcome. Therefore, we performed this randomized multicenter clinical trial in 
colorectal cancer patients to determine whether predeposit autologous blood transfusions 
would improve the prognosis and decrease the rate of infectious complications as 
compared with standard allogeneic blood transfusions (without buffy coat). 
Postoperative infectious complications 
lnununosuppression is linked to an increased susceptibility to infections and therefore it is 
conceivable that transfusion-induced immunosuppression is correlated with an increased 
rate of postoperative infectious complications. However, as discussed in more extent in 
chapter 5 we could not find support for a causal relationship between blood transfusions of 
any type (allogeneic or autologous) with infections. We only found an increased rate of 
infections when more than two units of blood were required, which is to our opinion 
supportive for the conclusion that an extensive surgical trauma and related blood loss is 
the real factor which affects the risk of infectious complications after colorectal cancer 
surgery. We will focus the general discussion on the putative detrimental relationship 
between blood transfusions and colorectal cancer prognosis. 
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Colorectal cancer prognosis 
This study shows that. although a remarkable reduction in the exposure to allogeneic blood 
transfusions was achieved by a predeposit autologous blood donation program. this 
reduction did neither decrease the rate of colorectal cancer recurrence or improved the 
survival of those patients. These findings led to the conclusion that there is no oncologic 
reason to use a predeposit autologous blood donation program in colorectal cancer 
patients. The study by Heiss et al.2 which had a comparable study design had too less 
patients (N=120) to draw reliable conclusions. The preliminary results of their intention-to-
treat analysis revealed also no benefits for patients randomized to the autologous group 
with regard to cancer prognosis (survival; p=O.204. recurrence rate; p=O.ll). A not 
randomized study found no differences in survival comparing autologous and allogeneic 
blood transfusions in patients who underwent radical surgery for prostate cancer.3 Another 
randomized study in colorectal cancer had a different study design to overcome the 
putative detrimental effects of allogeneic transfusions and was recently published by 
Houbiers et aI.' Based on the findings that the transfusion-induced immunosuppression 
might be mediated by the transfused leukocytes.' it was postulated that these effects might 
be prevented by removing the leukocytes as much as possible. Houbiers found in 
colorectal cancer patients no advantage on prognosis in the patients who had received 
leukocyte depleted blood as compared with those patients who had received allogeneic 
transfusions (without buffy coat). The authors concluded that. although there is no reason 
to transfuse leukocytes, there is no oncologic reason to make an effort to remove more 
than the buffy coat alone. 
To explore the relationship between blood transfusions and colorectal cancer prognosis our 
study was regarded as a nonrandomized study. In agreement with several retrospective 
studies it was demonstrated that the transfused patients had a significantly worse prognosis 
as compared with the patients who did not receive transfusions. The disease-free survival 
at 4 years was 59% and 73%. respectively. In multivariate analysis the relationship 
between transfusions and prognosis was about the same when the different types of 
transfusions (allogeneic and autologous) were compared. Because the transfusion of 
autologous blood was limited to two units subgroup analyses were performed by excluding 
the patients who received more than two transfusions. This multivariate analysis also 
showed an equal effect of allogeneic and of autologous transfused patients as compared 
with the patients who did not require transfusions. These findings may suggest that there 
is indeed a direct effect of allogeneic blood transfusions on prognosis. and that this effect 
also exists for autologous transfusions. 
ImmwlOmodulatioll by autologous blood transfusion 
Autologous blood transfusions in humans are comparable to syngeneic transfusions in 
animals. In the animal experiments showing a deleterious effect of allogeneic transfusions 
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on tumor growth no such effect was found when syngeneic blood transfusions were 
given."'" Although there was no experimental support for an effects of autologous 
transfusions on tumor growth, it was found that autologous transfusions could have an 
immunomodulatory effect as well. Recently, Perttilii et al. 9 found that the immunological 
changes after open heart surgery did not differ significantly between autologous, obtained 
by a cell saver, or allogeneic blood transfusions. These findings were however 
contradicted by Peller et al.1O who found that the transfusion of autologous blood 
improved impaired immune responses in cancer patients, whereas allogeneic transfusions 
did not. As a result of storage blood contains microaggregates of fibrin strands and 
degenerating leukocytes and platelets which bind to fibronectin. Fibronectin has a role in 
macrophage function. Due to the transfusion of stored blood (allogeneic or autologous) the 
fibronectin concentration is reduced in the recipient and therefore related immune 
functions may be impaired. Lawrance et al. l1 found that after storage of blood platelet 
derived growth factors were increased, which affected tumor growth. The storage of blood 
has also great impact on the synthesis of prostaglandin E, which may impair immune 
responses in the recipient. 12 Furthermore, the mitogenic activity of plasma is increased 
with a longer storage time.13 This increment of mitogenic activity becomes apparent after 
a storage time of about two weeks. 
bmmmomodulation by transfusion of plasma 
The suggestion that the negative effects of blood transfusions were due to factors present 
in plasma was supported by clinical studies which found that the transfusion-induced 
effects were a result of the plasma transfusion."'" In the study presented in this thesis 
the number of patients who received fresh-frozen plasma was too small to justify firm 
conclusions. A marked effect of packed cells (buffy coat depleted) was demonstrated. The 
recurrence rate for patients receiving allogeneic transfusions was 2.3, and for patients 
receiving autologous transfusions was 1.8 as compared with patients who did not require 
transfusions. In a recent meta-analysis a relationship between blood transfusions and poor 
prognosis of the same magnitude as our results was reported. 16 The cumulative odds-ratio 
of negative outcomes after perioperative blood transfusions in this meta-analysis was 1.80 
for recurrent disease. However, no effects of fresh-frozen plasma were found in this study. 
Blood transfusion and local recurrence 
The negative relationship between blood transfusions and colorectal cancer recurrence was 
unraveled in more extent by subdividing the endpoint of cancer recurrence into local 
recurrence and distant metastases. It was found that there was no relationship between 
blood transfusions of any type (allogeneic, autologous, or both types) and the incidence of 
distant metastases. However, the risk of having local recurrence was significantly 
increased for patients who received blood transfusions of any kind. The risk of local 
recurrence did not differ significantly between the different types of transfusions. 
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Obviously, local failure in colorectal cancer is more common in rectal cancer than in 
colonic cancer and rectal surgery is also associated with a greater need for transfusions. 
When the factor 'tumor location in the rectum' was investigated in this study, indeed this 
factor affected the risk of local recurrence. But, when multivariate analysis allowing also 
for tumor location was performed, no additional effect on prognosis of this factor was 
found. The need for blood transfusions was an independent factor affecting the risk of 
local recurrence. 
Local recurrence is related to surgical failure which suggests that the relationship between 
blood transfusions and impaired prognosis is not causal and is not induced by 
immunosuppression, but that this is an indirect association. Therefore, we conclude that 
not the blood transfusions themselves but rather the circumstances necessitating transfusion 
are the real determinants of prognosis in colorectal cancer patients. 
Blood loss alld cancer recurrence 
Speculations can be made which circumstances determine the need for transfusions. The 
most important factor is probably the amount of blood loss during surgery. Blood loss 
itself can induce immunosuppression. 17·ls And, it is also found that blood loss can 
stimulate tumor growth in animal experiments. I' To elucidate the effect of blood loss 
separately from the effect of blood transfusions in our randomized study is difficult, 
because, as a result of the transfusion rules, blood transfusions are strongly correlated to 
blood loss. In experimental studies blood loss without surgical trauma can be imitated by 
blood donation. Since in our randomized study we used predeposit autologous blood as an 
alternative for allogeneic transfusions, the patients randomized to the autologous group had 
to donate blood. The investigations on the putative immunological changes provoked by 
blood donation (blood loss without surgical trauma) revealed that the NK cell activity was 
significantly decreased after blood donation in colorectal cancer patients. When taken into 
account only those patients who did not require any transfusion (packed cells or plasma, 
autologous or allogeneic), the clinical consequences of this impaired NK cell function 
could be investigated. No significant impact of blood donation on the prognosis of 
colorectal cancer patients could be demonstrated in this study. 
As discussed above it is unlikely that immunological changes only affect the risk of local 
recurrence and not the risk of distant metastases. More likely is the explanation that blood 
loss and the need for blood transfusions are surrogate markers of surgical extent or 
trauma. This possible explanation of the negative association between transfUSIons and 
prognosis was already given by Hodgson and Lowenfels in 1982.2• 
Whether this view on the topic can explain all the findings from previous experimental 
and clinical studies will be further discussed. 
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Concluding remarks 
The finding that some animal models showed a tumor promoting effect of blood 
transfusions suggests that there indeed might be a clinical situation in which there is a 
direct effect of blood transfusions on tumor recurrence. This clinical situation could be 
present in only a specific tumor-host relationship and therefore difficult to find in clinical 
studies. The same variety in results was already found in animal experiments investigating 
the effect of blood transfusions and transplant survival. Although in clinical organ 
transplantation overall survival is increased by blood transfusions, stratification into 
subgroups revealed that about 30% of the patients respond with sensitization. Results from 
specific animal models already had indicated that this could have been anticipated. Thus, 
the variety in results from (inbred) animals reflects the variety in results that may occur in 
an outbred population. Therefore, the different findings from animal experiments provide 
information about the biological variation of a certain phenomenon. The whole spectrum 
of this variability may occur in a clinical situation, however, it is difficult to pinpoint 
where and when. 
The fact that so many controversial clinical reports were published suggests that whenever 
an association between blood transfusions and colorectal cancer prognosis exists it 
probably will be indirect and not causal. One of the reasons why those studies gave 
different outcomes might be that they also reflect the variability of the phenomena that 
may occur. It is also possible that the presence of a transfusion effect depends on the 
indication for transfusion, which can vary enormously between different centers. The 
controversy in clinical findings might also be explained by the variability among surgeons 
or tumors.'1 These tumor and surgeon related differences might influence the need for 
blood transfusions as well as the incidence of recurrent disease. Therefore, a negative 
association is found in some studies whereas this is not the case in others, which makes it 
more likely that the relationship between blood transfusions and colorectal cancer 
prognosis is noncausal but simply indirect. Furthermore, the suggestion that transfusion-
induced immunosuppression could influence the prognosis of colorectal cancer patients is 
based on the believe that tumor growth might be affected by subtle immunological 
changes. However, human colorectal cancer is not an immunogenic tumor and has so far 
not shown to be affected by immunosuppression. Although, some tumors occur more 
frequently in patients who received long-lasting immunosuppression this did not concern 
colorectal carcinoma.22.13 Additionally, immunotherapy reflecting sensitivity to immune 
responses in colorectal cancer had only marginal effects on prognosis.24,2S 
Putting together all the information coming from experimental studies, retrospective 
clinical studies, and randomized clinical studies which investigated whether blood 
transfusions adversely affect colorectal cancer prognosis we conclude that whenever such a 
relationship exists it is noncausal. The sobering final conclusion therefore is that not the 
blood transfusions themselves but rather the circumstances necessitating transfusion are the 
real determinants of prognosis in colorectal cancer. 
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Summary and conclusions 
Chapter 1 is the general introduction of this thesis and gives and overview of the 
literature related to the risks of blood transfusions. Especially, the induction of 
immunosuppression is discussed in relation to transplantation, cancer prognosis, and 
infectious complications after surgery. The relationship between blood transfusions and 
immunosuppression is, obviously. present and beneficial in patients receiving a 
transplantation. However, the question whether this transfusion-induced 
immunosuppression has a negative effect on prognosis or on infectious complications after 
colorectal surgery is not clear from experimental or clinical (mostly retrospective) studies 
so far. Therefore, there is a need for randomized studies to investigate whether this 
putative detrimental effect of allogeneic blood transfusions could be overcome. We have 
chosen to use a predeposit autologous blood donation program as an alternative for 
allogeneic blood transfusion. At the end of chapter I the aims of the study are presented. 
Chapter 2 gives in extent the material and methods of the randomized multicenter trial in 
which the value of a predeposit autologous blood transfusion program in colorectal cancer 
patients is investigated. The results of the study are given regarding the intention-to·treat 
principle. The colorectal cancer-specific survival at 4 years was 67% in the allogeneic 
group and 62% in the autologous group (p=O.39). Among the 423 patients who underwent 
curative surgery, 66% of those in the allogeneic group and 63% of those in the autologous 
group had no recurrence of colorectal cancer at 4 years (p=O.93). It was concluded that a 
significant reduction of exposure to allogeneic blood transfusions was achieved by our 
donation program. However, no significant differences with regard to survival (overall or 
colorectal cancer specific) or disease-free survival were found for patients randomized to 
either the allogeneic or autologous group. Although the transfused patients had a worse 
prognosis as compared with patients who did not receive transfusions, there was no 
difference between the patients receiving either I or 2 allogeneic transfusions or I or 2 
autologous transfusions. The relative risks of recurrence were 2.1 and 1.8, respectively. 
Chapter 2: 'Letters to the editor' presents two letters which were published as a reaction 
to chapter 2. An authors reply was given in which the effects of fresh· frozen plasma on 
colorectal cancer prognosis is given. No detrimental effects of either allogeneic or 
autologous plasma transfusions on prognosis were demonstrated in this study. It is, 
however, important to realize that the number of patients receiving fresh-frozen plasma 
was too small to allow reliable conclusions. 
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Chapter 3 elaborates more on the worse prognosis for transfused patients as compared 
with patients who did not receive transfusions. The disease-free survival at 4 years were 
59% and 73%, respectively. Multivariate analysis, allowing for various prognostic factors, 
showed that there was no difference in prognosis between the randomized groups. The 
only factors influencing the rate of recurrence were the Dukes' classification and whether 
blood transfusions were given or not. This analysis also revealed that patients receiving 
only allogeneic or only autologous transfusions, and patients receiving both types of 
transfusions all had a significant increased risk of recurrence as compared with patients 
who did not require transfusions. No significant differences in prognosis were found in 
comparing these three groups of transfused patients. 
Chapter 4 unravels in more extent the negative association found in the previous chapter. 
When recurrent disease was subdivided into local recurrence and distant metastases it was 
found that there was no relationship between blood transfusions and the incidence of 
patients having distant metastases. However, there was a significant higher incidence of 
patients having local recurrence in the transfused groups of patients. Multivariate analysis, 
allowing also for Dukes' classification and tumor location showed that the relative risk of 
local recurrence was 5.2 in the transfused group of patients. A significantly increased risk 
of local recurrence was found for all the transfused patients, irrespective of the type 
(allogeneic, autologous, or both types) of blood transfusions given. Because local 
recurrences seems to be related to surgical failure, it was concluded that not the blood 
transfusions themselves but rather the circumstances necessitating them are the real 
predictors of prognosis in colorectal cancer. 
Chapter 5 shows the results of the randomized study with regard to the rate of 
postoperative infectious complications. It was found that the incidence of postoperative 
infections after colorectal cancer surgery was not significantly different between allogeneic 
and autologous group. In the allogeneic group 25% of the patients had infections as 
compared with 27% in the autologous group. Because the incidence of infections can vary 
per hospital the influence of the multicentricity of the study was investigated. We did not 
find any effect of this with regard to infections. 
It also was found that patients who received more than two units of blood had an 
significantly increased risk of infections as compared with patients receiving 1 or 2 
transfusions or no transfusion at all. When two units, irrespective whether they were of the 
allogeneic or autologous type, were transfused there was no increase in the risk of 
infections as compared with the patients who did not require transfusions. We conclude 
that the risk of infections is not causally related to transfusions but that the circumstances 
necessitating transfusions increase the risk of infections. 
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Chapter 6 presents immunological studies to explore the effect of blood donation in 
healthy blood donors and in colorectal cancer patients. No effect of donation was found on 
the proportion of B, T, and NK cells assessed by flow cytometric analysis. T cell function 
was investigated by PHA stimulation and appeared not to be affected by blood donation. 
However, a significant depression of NK cell activity after donation was found in normal 
blood donors and in colorectal cancer patients. Colorectal cancer patients had after 
donation of two units of blood 54% of the NK cell activity left as before donation. 
Therefore, the NK cell activity of the patients in the autologous group was significantly 
less as compared with the patients in the allogeneic group. 
Chapter 7 deals with the clinical implication of the immunological changes in colorectal 
cancer patients who donated two units of blood for autologous transfusions. To evaluate 
the effect of donation, all the patients who needed transfusion were excluded from this 
analysis. It was found that the risk of colorectal cancer recurrence and the survival was 
not affected by blood donation. The disease-free survival at 4 years was 78% in the 
donation group, whereas it was 74% in the group of patients who did not donate blood. 
It also was shown that patients who donated blood had no increased risk of infectious 
complications after surgery as compared with the patients who did not donate blood. The 
rate of infections was 16% in the donation group as compared with 22% in the group of 
patients who did not donate blood. Therefore we conclude that, although the NK cell 
function was lower in patients who donated blood, this had no clinical implication with 
regard to prognosis and infection. 
Chapter 8 is the general discussion of this thesis. It gives and overview of the results of 
the studies presented in this thesis. The results and the putative explanations for the 
findings are discussed. 
Conclusions 
1. A predeposit autologous blood transfusion program did neither improve the 
survival nor reduced the recurrence rate in colorectal cancer patients. 
2. Although a reduction of exposure to allogeneic blood is of benefit, there is no 
oncologic reason to use a predeposi! autologous blood donation program in 
colorectal cancer patients. 
3. The association between blood transfusions and colorectal cancer prognosis is the 
same for allogeneic as for autologous blood. 
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4. The risk of local recurrence is associated with the need for blood transfusions, 
whereas the risk of distant metastases is not. 
5. Not the blood transfusions themselves but rather the circumstances necessitating 
transfusion are the real determinants of prognosis in colorectal cancer patients. 
6. A predeposit autologous blood transfusion program does not reduce the rate of 
infectious complications after colorectal cancer surgery. 
7. The need for more than two units of blood increased the risk of infectious 
complications, not mattering whether the first two transfusions were allogeneic or 
autologous. 
8. Although blood donation leads to a decreased natural killer cell activity in 
colorectal cancer patients, this impaired natural killer cell function had not clinical 
impact on prognosis and on the rate of postoperative infectious complications. 
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Samellvattillg en cone/usies 
Samenvatting en conclusies 
Hoofdstuk 1 is de algemene introductie van dit proefschrift en geeft een overzicht van de 
literatuur over de risico's van bloedtransfusies. Besproken wordt met name het induceren 
van immunosuppressie in relatie tot transplantatie, oncologische prognose en 
postoperatieve infectieuze complicaties. De relatie tussen bloedtransfusies en 
immunosuppressie is heel duidelijk aanwezig en gunstig voor pati~nten die een 
transplantatie ondergaan. De vraag eehter of deze immunosuppressie een negatief effect 
heeft op de prognose en de infectieuze complicaties na colorectale chirurgie is door 
experimentele en klinische (meestal retrospeetieve) studies tot nu toe niet duidelijk 
geworden. Daarom was er behoefte aan gerandomiseerd onderzoek om na te gaan of deze 
mogelijk negatieve effecten van allogene bloedtransfusies voorkomen kunnen worden. Wij 
hebben gekozen am preoperatief gedoneerde alltologe bloedtransfusies te gebruiken als 
alternatief voor allogene transfusies. Aan het eind van hoofdstuk I worden de 
doelstellingen van de studie uiteengezet. 
Hoofdstuk 2 bespreekt uitgebreid de opzet van de gerandomiseerde multicenter studie 
waarin de waarde van een autoloog bloedtransfusie programma in pati~nten met 
colorectaal carcinoom wordt onderzocht. De resultaten van de studie worden gegeven met 
betrekking tot het intention-to-treat principe. De overleving na 4 jaar was 67% in de 
allogene groep en 62% in de alltologe groep (p=O.39). Van de 423 patienten die euratief 
geopereerd werden had 66% in de allogene groep en 63% in de alltologe groep na 4 jaar 
geen recidief van het colorectale carcinoom (p=O.93). Br wordt geconc1udeerd dat een 
significante reductie van blootstelling aan allogene bloedtransfusies was bereikt met ons 
donatie programma. Br werden echter geen significante verschillen in overleving of in 
ziektevrije overleving gevonden tussen de pati~nten die gerandomiseerd waren voor de 
allogene of voor de autologe groep. Hoewel de getransfundeerde patienten een slechtere 
prognose hadden dan de patienten die niet getransfundeerd werden, waren er geen 
versehillen tussen de patienten die I of 2 allogene of die I of 2 alltologe transfusies 
kregen. Het relatieve risico op een recidief was respectievelijk 2,1 en 1,8. 
Hoofdstuk 2: 'Letters to the editor' bevat 2 brieven die werden gepubliceerd als een 
reactie op hoofdstuk 2. Br wordt een 'authors reply' gegeven waarin de effecten van fresh-
frozen plasma op de prognose van pati~nten met een colorectaal carcinoom worden 
besproken. In deze studie worden geen negatieve effecten op de prognose gevonden van 
zowel allogeen als van autoloog plasma. Het is echter wei belangrijk om zich te realiseren 
dat de aantallen pati~nten die plasma kregen te klein was om betrouwbare conclusies te 
trekken. 
115 
Samellvatting ell cOllciusies 
Hoofdstuk 3 behandelt uitvoeriger de slechtere prognose van getransfundeerde patienten 
vergeleken met patienten die niet getransfundeerd werden. De ziektevrije overleving na 4 
jaar was respectievelijk 59% en 73%. Multivariate analyse, rekening houdend met 
verschillende prognostische factoren, liet geen verschil in prognose zien tussen de 
gerandomiseerde groepen. De Dukes' classificatie en het al dan niet krijgen van 
bloedtransfusies waren de enige factoren die de recidiefkans be'invloedden. Deze analyse 
toonde ook dat patienten die aHeen aHogene of aHeen autologe transfusies kregen en 
patienten die beide soorten transfusies kregen allen een significant hogere kans op een 
recidief hadden dan de patienten die geen transfusies nodig hadden. Er werd geen 
significant verschil gevonden tussen deze drie groepen getransfundeerde patienten. 
Hoofdstuk 4 onderzoekt uitvoeriger de negatieve relatie welke in het vorige hoofdstuk 
werd gevonden. Als recidief wordt onderverdeeld in lokaal recidief en afstandsmetastasen, 
dan wordt er geen relatie gevonden tussen bloedtransfusies en de kans op 
afstandsmetastasen. Er wordt echter wei een significant hogere kans op het krijgen van een 
lokaal recidief gevonden in de groep patienten die getransfundeerd werden. Multivariate 
analyse, rekening houdend met de Dukes' classificatie en tumor lokalisatie, toonde dat het 
relatieve risico op lokaal recidief 5,2 was in de groep patienten die getransfundeerd 
werden. Een significant verhoogd risico op lokaal recidief werd gevonden in ane groepen 
patienten die transfusies kregen. Dit verhoogde risico was onafhankelijk van het soort 
bloedtransfusie (allogeen, autoloog of beide soorten). Omdat de kans op een lokaal recidief 
gerelateerd lijkt aan chirurgisch falen, wordt geconcludeerd dat niet de bloedtransfusies 
zelf maar de omstandigheden die transfusies nodig maken de prognose bij het colorectaal 
carcinoom bepalen. 
Hoofdstuk 5 toont de resultaten van de gerandomiseerde studie met betrekking tot de 
incidentie van postoperatieve infectieuze complicaties. Er werd gevonden dat de incidentie 
van postoperatieve infectieuze complicaties na colorectale chirurgie niet significant 
verschilde tussen de aHogene en autologe groep. In de aHogene groep had 25% van de 
patienten infecties vergeleken met 27% in de autologe groep. Omdat de kans op infecties 
per ziekenhuis kan verschillen werd de invloed van multicentriciteit van de studie 
onderzocht. Wij konden geen invloed hiervan op de infectiekans vinden. 
Er werd ook gevonden dat de patienten die meer dan 2 eenheden bloed kregen een 
significant hogere kans op infecties hadden vergeleken met patienten die I of 2 transfusies 
of helemaal geen transfusies kregen. Wanneer 2 eenheden getransfundeerd werden, 
onafhankelijk of deze allogeen of autoloog waren, was er geen verhoogde infectiekans 
vergeleken met de patienten die geen transfusies kregen. Wij concluderen dat de kans op 
infectieuze complicaties niet causaal gereiateerd is aan bloedtransfusies, maar dat de 
omstandigheden die transfusies nodig maken de kans op infecties vergroot. 
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Hoofdslnk 6 geeft de immunologische studies die het effect van bloeddonatie onderzoeken 
in gezonde bloeddonoren en in patienten met een eoloreetaal earcinoom. Donatie heeft 
geen effect op de verhoudingen van B, T, en NK cellen, welke bepaald werden met flow 
cytometrie. De T cel functie werd onderzocht middels PHA stimulatie en bleek niet 
beihvloed te worden door bloeddon.tie. Er werd echter een significante daling van de NK 
eel aetiviteit na donatie gevonden in normale bloeddonoren en in patienten met een 
eolorectaal eareinoom. Patienten met een eolorectaal careinoom hadden na donatie van 2 
eenheden bloed nog 54% van de NK cel activiteit van voor donatie over. 
Hoordslnk 7 behandelt de klinische implicaties van de inununologische veranderingen in 
patienten met een colorectaal earcinoom die 2 eenheden bloed hebben gedoneerd voor 
autologe transfusie. Om het effect van bloeddonatie te evalueren werden aBe patienten die 
transfusies nodig hadden uitgesloten van deze analyse. Er werd gevonden dat het risico op 
recidief en de overleving niet werden bei'nvloed door bloeddonatie. De ziektevrije 
overleving na 4 jaar was 78% in de groep patienten die doneerden, terwijl dit 74% was in 
de groep patiCnten die niet doneerden. 
Er werd ook gevonden dat patienten die bloed doneerden geen hogere kans hadden op het 
krijgen van postoperatieve infectieuze complieaties dan patienten die niet doneerden. Het 
percentage infectie was 16% in de donatie groep vergeleken met 22% in de groep 
patienten die geen bloed gaf. Daarom concluderen wij dat, hoewel de NK cel activiteit 
lager is in patienten die bloed doneerden, dit geen kiinische gevolgen heeft met betrekking 
tot de prognose en de infectiekans. 
Hoordslnk 8 is de algemene discussie van dit proefschrift. Het geeft een overzicht van de 
resultaten van de studies uit dit proefschrift. De resultaten en de mogelijke verkiaringen 
VOOf de bevindingen worden uiteengezet. 
Conclnsies 
1. Een preoperatief .utoloog bloedtransfusie progranuna verbetert de overleving niet 
en vermindert de kans op reeidief niet bij patienten met een colorectaal carcinoom. 
2. Hoewel een reductie van blootstelling aan allogeen bloed voordeJig is, is er geen 
oncologische reden om een preoperatief autoloog bloeddonatie programma te 
gebruiken in patienten met een colorectaal carcinoom. 
3. Het verband tussen bloedtransfusies en prognose van het colorectale carcinoom is 
hetzelfde voor allogeen als voor autoloog bloed. 
4. De kans op lokaal recidief is gerelateerd aan de noodzaak om te transfunderen, 
terwijl dit niet geldt voor de kans op afstandsmetastasen. 
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5. Niet de bloedtransfusies zelf maar de omstandigheden die transfusies nodig maken 
bepalen de prognose bij patienten met een colorectaal carcinoom. 
6. Een preoperatief autoloog bloeddonatie programma verlaagt de incidentie van 
infectieuze complicaties na colorectale chirurgie niet. 
7. Indien meer dan 2 eenheden bloed nodig zijn is de kans op infectieuze complicaties 
vergroot, onafhankeIijk of de eerste 2 transfusies allogeen of autoloog waren. 
8. Hoewel bloeddonatie de NK eel activiteit verlaagt, heef! deze verlaging geen 
klinische betekenis voor de prognose en de incidentie van postoperatieve 
complicaties bij patienten met een colorectaal carcinoom. 
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List of abbreviations 
AIDS 
allo 
auto 
Ci 
em 
cpm 
Cr 
FFP 
FITC 
gldl 
HLA 
KLH 
mmol/l 
ml 
MR 
NK cell 
n,s. 
PE 
PHA 
SD 
SEM 
SR 
fll 
acquired immune deficiency syndrome 
allogeneic 
autologous 
Curle 
centimeter 
count per minute 
chrome 
fresh-frozen plasma 
fluorocein isothiocyanate. green fluorescence 
gram per deciliter 
human leukocyte antigen 
keyhole-limpet hemocyanin 
millimol per liter 
milliliter 
maximal release 
natural killer cell 
not significant 
phycoerythrin, red fluorescence 
phytohemagglutinin 
standard deviation 
standard error of the mean 
spontaneous release 
microliter 
Hemoglobin level of 1.0 gldl = 0.62 mmol/l 
Hemoglobin level of 1.0 mmol/l = 1.61 gldl 
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